<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INVOKAMET- canagliflozin and metformin hydrochloride tablet, film coated </strong><br>Janssen Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use INVOKAMET<span class="Sup">®</span> safely and effectively. See full prescribing information for INVOKAMET.<br><br>INVOKAMET (canagliflozin and metformin hydrochloride) tablets, for oral use<br>Initial U.S. Approval – 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue INVOKAMET and hospitalize the patient immediately (<a href="#S5.1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left">Warnings and Precautions (<a href="#S5.9">5.9</a>)</td>
<td align="right">09/2015</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue INVOKAMET and hospitalize the patient immediately (<a href="#S5.1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">INVOKAMET is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin or in patients already being treated with both canagliflozin and metformin (<a href="#S1">1</a>) </p>
<p class="Highlighta"><span class="Underline">Limitation of use:</span> </p>
<p class="Highlighta">Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (<a href="#S1">1</a>) </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Individualize based on the patient's current regimen (<a href="#S2">2</a>)</li>
<li>Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin (<a href="#S2.1">2.1</a>)</li>
<li>Do not exceed a daily dose of metformin 2,000 mg and canagliflozin 300 mg; INVOKAMET is limited to canagliflozin 50 mg twice daily in patients with an eGFR of 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span> (<a href="#S2.1">2.1</a>, <a href="#S2.2">2.2</a>)</li>
<li>Assess renal function before initiating INVOKAMET. Do not initiate or continue INVOKAMET if creatinine levels are greater than or equal to 1.5 mg/dL for males or 1.4 mg/dL for females, or if eGFR is persistently below 45 mL/min/1.73 m<span class="Sup">2</span> (<a href="#S2.2">2.2</a>, <a href="#S4">4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Film-coated tablets: </p>
<ul class="Disc">
<li>Canagliflozin 50 mg and metformin hydrochloride 500 mg</li>
<li>Canagliflozin 50 mg and metformin hydrochloride 1,000 mg</li>
<li>Canagliflozin 150 mg and metformin hydrochloride 500 mg</li>
<li>Canagliflozin 150 mg and metformin hydrochloride 1,000 mg (<a href="#S3">3</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, ESRD, or on dialysis (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (<a href="#S1">1</a>, <a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</li>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to canagliflozin or metformin (<a href="#S4">4</a>, <a href="#S5.8">5.8</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span></span>: Warn against excessive alcohol use. INVOKAMET is not recommended in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxic</span> states. Ensure normal renal function before initiating and at least annually thereafter (<a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>, <a href="#S5.5">5.5</a>, <a href="#S5.11">5.11</a>, <a href="#S5.12">5.12</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>: Before initiating INVOKAMET, assess volume status and correct <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the elderly, in patients with low systolic blood pressure, or on diuretics, ACEi, or ARB. Monitor for signs and symptoms during therapy (<a href="#S5.2">5.2</a>)</li>
<li>
<span class="Underline">Impairment in Renal Function</span>: Monitor renal function during therapy (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Underline">Radiological Studies and Surgical Procedures</span>: Temporarily discontinue for radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span>: Monitor potassium levels in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and in patients predisposed to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#S2.2">2.2</a>, <a href="#S5.4">5.4</a>, <a href="#S6.1">6.1</a>, <a href="#S8.6">8.6</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span>: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with INVOKAMET (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Underline">Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span>: Monitor and treat if indicated (<a href="#S5.7">5.7</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span>: Discontinue INVOKAMET and monitor until signs and symptoms resolve (<a href="#S5.8">5.8</a>)</li>
<li>
<span class="Underline">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span></span>: Consider factors that contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk before initiating INVOKAMET (<a href="#S5.9">5.9</a>)</li>
<li>
<span class="Underline">Vitamin B<span class="Sub">12</span> deficiency</span>: Metformin may lower vitamin B<span class="Sub">12</span> levels. Monitor hematologic parameters annually (<a href="#S5.10">5.10</a>)</li>
<li>
<span class="Underline">Increased LDL-C</span>: Monitor LDL-C and treat if appropriate (<a href="#S5.13">5.13</a>)</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Most common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and increased urination (<a href="#S6.1">6.1</a>)</li>
<li>Most common adverse reactions associated with metformin (5% or greater incidence) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#S6.1">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Cationic drugs</span>: May reduce metformin elimination (<a href="#S7.1">7.1</a>)</li>
<li>
<span class="Underline">UGT inducers</span> (e.g., rifampin): Canagliflozin exposure is reduced. Consider increasing canagliflozin dose from 50 mg to 150 mg twice daily (<a href="#S2.3">2.3</a>, <a href="#S7.2">7.2</a>)</li>
<li>
<span class="Underline">Digoxin</span>: Monitor digoxin levels (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Pregnancy</span>: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus (<a href="#S8.1">8.1</a>)</li>
<li>
<span class="Underline">Nursing mothers</span>: Discontinue drug or nursing (<a href="#S8.3">8.3</a>)</li>
<li>
<span class="Underline">Geriatrics</span>: Higher incidence of adverse reactions related to reduced intravascular volume (<a href="#S5.2">5.2</a>, <a href="#S6.1">6.1</a>, <a href="#S8.5">8.5</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span>: Higher incidence of adverse reactions related to reduced intravascular volume and renal function (<a href="#S2.2">2.2</a>, <a href="#S5.3">5.3</a>, <a href="#S8.6">8.6</a>)</li>
</ul></div>
<div><div><div>
<div></div>
<div></div>
<div></div>
</div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Recommended Dosage for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Impairment in Renal Function</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Impaired Hepatic Function</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use of Sulfonylurea or Insulin</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Vitamin B<span class="Sub">12</span> Levels</a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Alcohol Intake</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Increases in Low-Density Lipoprotein (LDL-C)</a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Drug Interactions with Metformin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drug Interactions with Canagliflozin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Canagliflozin as Add-on Combination Therapy with Metformin</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Canagliflozin Compared to Glimepiride, Both as Add-on Combination Therapy with Metformin</a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Canagliflozin as Add-on Combination Therapy with Metformin and Sulfonylurea</a></h2>
<h2><a href="#section-13.4" class="toc">14.4	Canagliflozin Compared to Sitagliptin, Both as Add-on Combination Therapy with Metformin and Sulfonylurea</a></h2>
<h2><a href="#section-13.5" class="toc">14.5	Canagliflozin as Add-on Combination Therapy with Metformin and Pioglitazone</a></h2>
<h2><a href="#section-13.6" class="toc">14.6	Canagliflozin as Add-on Combination Therapy with Insulin (With or Without Other Anti-Hyperglycemic Agents, Including Metformin)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<ul class="Bold">
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</li>
<li>The onset is often subtle, accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>.</li>
<li>Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate.</li>
<li>If <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> is suspected, INVOKAMET<span class="Sup">®</span> should be discontinued and the patient hospitalized immediately <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">INVOKAMET (canagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin, or in patients who are already treated with both canagliflozin and metformin<span class="Italics"> [see <a href="#S14">Clinical Studies (14)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Underline">Limitations of Use</span></p>
<p>INVOKAMET is not recommended in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosage</h2>
<ul class="Disc">
<li> Individualize the starting dose of INVOKAMET (canagliflozin and metformin hydrochloride) based on the patient's current regimen: 						<dl>
<dt>–</dt>
<dd>    In patients on metformin, switch to INVOKAMET containing canagliflozin 50 mg with a similar total daily dose of metformin;</dd>
<dt>–</dt>
<dd>    In patients on canagliflozin, switch to INVOKAMET containing metformin 500 mg with a similar total daily dose of canagliflozin;</dd>
<dt>–</dt>
<dd>    In patients already treated with canagliflozin and metformin, switch to INVOKAMET containing the same total daily doses of each component.</dd>
</dl>
</li>
<li>Take INVOKAMET twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin <span class="Italics">[see <a href="#S3">Dosage Forms and Strengths (3)</a>].</span>
</li>
<li>In patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> not previously treated with canagliflozin, correct this condition before initiating INVOKAMET <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>, <a href="#S8.5">Use in Specific Populations (8.5)</a>, <a href="#S8.6">(8.6)</a>, and <a href="#S17">Patient Counseling Information (17)</a>]</span>.</li>
<li>Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and canagliflozin 300 mg in patients with an eGFR of 60 mL/min/1.73 m<span class="Sup">2</span> or greater <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Recommended Dosage for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<ul class="Disc">
<li>Assess renal function before initiating INVOKAMET and periodically thereafter.</li>
<li>Do not initiate or continue INVOKAMET in patients with serum creatinine levels greater than or equal to 1.5 mg/dL for males or 1.4 mg/dL for females. In patients who meet these serum creatinine levels, do not initiate or continue INVOKAMET if eGFR is persistently less than 45 mL/min/1.73 m<span class="Sup">2 </span><span class="Italics"> [see <a href="#S4">Contraindications (4)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</li>
<li>No dose adjustment of INVOKAMET is needed in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR of 60 mL/min/1.73 m<span class="Sup">2</span> or greater).</li>
<li>Limit the dose of INVOKAMET to canagliflozin 50 mg twice daily in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with an eGFR of 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers</h2>
<p class="First">If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKAMET, consider increasing the dose to canagliflozin 150 mg twice daily in patients currently tolerating 50 mg twice daily who have an eGFR of 60 mL/min/1.73 m<span class="Sup">2</span> or greater and require additional glycemic control <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</p>
<p>Consider another antihyperglycemic agent in patients with an eGFR of 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span> receiving concurrent therapy with a UGT inducer.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">INVOKAMET (canagliflozin and metformin hydrochloride) film-coated tablets for oral administration are available in the following strengths:</p>
<ul class="Disc">
<li>Canagliflozin 50 mg and metformin hydrochloride 500 mg tablets are immediate-release, capsule-shaped, white film-coated tablets with "CM" on one side and "155" on the other side.</li>
<li>Canagliflozin 50 mg and metformin hydrochloride 1,000 mg tablets are immediate-release, capsule-shaped, beige, film-coated tablets with "CM" on one side and "551" on the other side.</li>
<li>Canagliflozin 150 mg and metformin hydrochloride 500 mg tablets are immediate-release, capsule-shaped, yellow, film-coated tablets with "CM" on one side and "215" on the other side.</li>
<li>Canagliflozin 150 mg and metformin hydrochloride 1,000 mg tablets are immediate-release, capsule-shaped, purple, film-coated tablets with "CM" on one side and "611" on the other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">INVOKAMET is contraindicated in patients with:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (e.g., serum creatinine levels greater than or equal to 1.5 mg/dL for males or 1.4 mg/dL for females, <span class="Italics Underline">or</span> eGFR is less than 45 mL/min/1.73 m<span class="Sup">2</span>) which may also result from conditions such as <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>; end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) or patients on dialysis <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>, <a href="#s5.3">(5.3)</a> and <a href="#s8.6">Use in Specific Populations (8.6)</a>]</span>.</li>
<li>Acute or chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to canagliflozin or metformin <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with INVOKAMET and is fatal in approximately 50% of cases. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> may also occur in association with a number of pathophysiologic conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and whenever there is significant tissue <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is characterized by elevated blood lactate levels (greater than 5 mmol/L), decreased blood pH, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> with an increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and an increased lactate/<span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> ratio. When metformin is implicated as the cause of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, metformin plasma levels greater than 5 mcg/mL are generally found.</p>
<p>The reported incidence of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin is approximately 0.03 cases/1000 patient-years (with approximately 0.015 fatal cases/1000 patient-years). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Reported cases have occurred primarily in diabetic patients with significant <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including both intrinsic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and renal <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> requiring pharmacologic management, particularly when accompanied by <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> due to unstable or acute failure, are at increased risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of renal dysfunction and the patient's age. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Metformin treatment should not be initiated in any patients unless measurement of creatinine clearance demonstrates that renal function is not reduced. In addition, metformin should be promptly withheld in the presence of any condition associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p>Because impaired hepatic function may significantly limit the ability to clear lactate, metformin should be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients should be cautioned against excessive alcohol intake when taking metformin, since alcohol potentiates the effects of metformin on lactate metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure necessitating restricted intake of food or fluids <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S5.5">(5.5)</a>, <a href="#S5.11">(5.11)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> often is subtle, and accompanied by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. More severe <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> may be associated with signs such as <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and resistant <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>. Patients should be educated to recognize and promptly report these symptoms. If present, INVOKAMET should be discontinued until <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> is ruled out. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> in patients on a chronic, stable dose of metformin could be caused by <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</p>
<p>To rule out <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, serum electrolytes, <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful. Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may be due to other mechanisms, such as poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, vigorous physical activity, or technical problems in sample handling<span class="Italics">.</span></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> should be suspected in any diabetic patient with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> lacking evidence of <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> (<span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span> and <span class="product-label-link" type="condition" conceptid="4060404" conceptname="Acetonemia">ketonemia</span>). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital setting. In a patient with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Metformin is dialyzable (clearance of up to 170 mL/min under good hemodynamic conditions) and prompt hemodialysis is recommended to remove the accumulated metformin and correct the <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Such management often results in prompt reversal of symptoms and recovery <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Canagliflozin causes intravascular volume contraction. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> can occur after initiating INVOKAMET <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span> particularly in patients with eGFR less than 60 mL/min/1.73 m<span class="Sup">2</span>, elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with low systolic blood pressure. Before initiating INVOKAMET in patients with one or more of these characteristics who were not already on canagliflozin, volume status should be assessed and corrected. Monitor for signs and symptoms after initiating therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Impairment in Renal Function</h2>
<p class="First">Canagliflozin increases serum creatinine and decreases eGFR. Patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> may be more susceptible to these changes. Renal function abnormalities can occur after initiating INVOKAMET <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
<p>Metformin is known to be substantially excreted by the kidney. The risk of metformin accumulation and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of impairment of renal function. Therefore, INVOKAMET is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>, and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
<p>Before initiation of INVOKAMET therapy and at least annually thereafter, assess renal function <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>. In patients in whom development of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is anticipated (e.g., elderly), assess renal function more frequently and discontinue INVOKAMET if evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is present (e.g. serum creatinine levels greater than or equal to 1.5 mg/dL for males or 1.4 mg/dL for females, or eGFR is less than 45 mL/min/1.73 m<span class="Sup">2</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Underline">Use of Concomitant Medications That May Affect Renal Function or Metformin Disposition</span></p>
<p>Monitor and adjust dose of INVOKAMET or concomitant drug in patients taking medication(s) that may affect renal function or result in a significant hemodynamic change or interfere with the disposition of metformin <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First"><span class="Underline">Radiological Studies and Surgical Procedures</span></p>
<p>Radiologic studies involving the use of intravascular iodinated contrast materials (e.g., intravenous urogram, intravenous cholangiography, angiography, and computed tomography) can lead to acute alteration of renal function and have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin. Therefore, in patients in whom any such study is planned, temporarily discontinue INVOKAMET at the time of or prior to the procedure, and withhold for 48 hours subsequent to the procedure and reinstitute only after renal function has been confirmed to be normal.</p>
<p>Temporarily discontinue INVOKAMET for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and restart after the patient's oral intake has resumed and renal function has been evaluated as normal.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Canagliflozin can lead to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who are taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, or medications that interfere with the renin-angiotensin-aldosterone system are at an increased risk of developing <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
<p>Monitor serum potassium levels periodically after initiating INVOKAMET in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and in patients predisposed to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> due to medications or other medical conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Impaired Hepatic Function</h2>
<p class="First">Metformin use in patients with impaired hepatic function has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Therefore, INVOKAMET is not recommended in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use of Sulfonylurea or Insulin</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Insulin and insulin secretagogues are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Canagliflozin can increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when combined with insulin or an insulin secretagogue <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with INVOKAMET.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6.2"></a><p></p>
<p class="First">Metformin</p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">pituitary insufficiency</span> or alcohol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, are particularly susceptible to hypoglycemic effects. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Monitor for a need to lower the dose of INVOKAMET to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Canagliflozin increases the risk of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Patients with a history of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and uncircumcised males were more likely to develop genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Monitor and treat appropriately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>), some serious, were reported with canagliflozin treatment; these reactions generally occurred within hours to days after initiating canagliflozin. If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, discontinue use of INVOKAMET; treat and monitor until signs and symptoms resolve <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">An increased risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, occurring as early as 12 weeks after treatment initiation, was observed in patients using canagliflozin. Consider factors that contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk prior to initiating INVOKAMET <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Vitamin B<span class="Sub">12</span> Levels</h2>
<p class="First">In controlled, 29-week clinical trials of metformin, a decrease to subnormal levels of previously normal serum vitamin B<span class="Sub">12</span> levels, without clinical manifestations, was observed in approximately 7% of metformin-treated patients. Such decreases, possibly due to interference with B<span class="Sub">12</span> absorption from the B<span class="Sub">12</span>-intrinsic factor complex, is, however, very rarely associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or neurologic manifestations due to the short duration (less than 1 year) of the clinical trials. This risk may be more relevant to patients receiving long-term treatment with metformin and adverse hematologic and <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic reactions</span> have been reported postmarketing. The decrease in vitamin B<span class="Sub">12</span> levels appears to be rapidly reversible with discontinuation of metformin or vitamin B<span class="Sub">12</span> supplementation. Measure hematologic parameters on an annual basis in patients on INVOKAMET and investigate and treat if abnormalities occur. Patients with inadequate vitamin B<span class="Sub">12</span> or calcium intake or absorption may be predisposed to developing subnormal vitamin B<span class="Sub">12</span> levels, and routine serum vitamin B<span class="Sub">12</span> measurement at 2- to 3-year intervals is recommended in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Alcohol Intake</h2>
<p class="First">Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake while receiving INVOKAMET <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) from whatever cause (e.g., acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and other conditions characterized by <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>) have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may also cause prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. When such events occur, promptly discontinue INVOKAMET <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Increases in Low-Density Lipoprotein (LDL-C)</h2>
<p class="First">Dose-related increases in LDL-C occur with canagliflozin <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Monitor LDL-C and treat if appropriate after initiating INVOKAMET.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with INVOKAMET or any other antidiabetic drug <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are also discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S5.3">(5.3)</a>, <a href="#S5.5">(5.5)</a>, <a href="#S5.11">(5.11)</a>, <a href="#S5.12">(5.12)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Impairment in Renal Function <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Impaired Hepatic Function <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use of Sulfonylurea or Insulin <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li>Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>
</li>
<li>Vitamin B<span class="Sub">12</span> Deficiency <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>
</li>
<li>Increases in Low-Density Lipoprotein (LDL-C) <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First">Pool of Placebo-Controlled Trials</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p>The data in Table 1 is derived from four 26-week placebo-controlled trials. In one trial canagliflozin was used as monotherapy and in three trials canagliflozin was used as add-on therapy with metformin (with or without other agents) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. These data reflect exposure of 1667 patients to canagliflozin and a mean duration of exposure to canagliflozin of 24 weeks with 1275 subjects exposed to a combination of canagliflozin and metformin. Patients received canagliflozin 100 mg (N=833), canagliflozin 300 mg (N=834) or placebo (N=646) once daily. The mean daily dose of metformin was 2138 mg (SD 337.3) for the 1275 subjects in the three placebo-controlled metformin add-on studies. The mean age of the population was 56 years and 2% were older than 75 years of age. Fifty percent (50%) of the population was male and 72% were Caucasian, 12% were Asian, and 5% were Black or African American. At baseline the population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 7.3 years, had a mean HbA1C of 8.0% and 20% had established microvascular complications of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Baseline renal function was normal or mildly impaired (mean eGFR 88 mL/min/1.73 m<span class="Sup">2</span>).</p>
<p>Table 1 shows common adverse reactions associated with the use of canagliflozin. These adverse reactions were not present at baseline, occurred more commonly on canagliflozin than on placebo, and occurred in at least 2% of patients treated with either canagliflozin 100 mg or canagliflozin 300 mg.</p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1: Adverse Reactions From Pool of Four 26−Week Placebo-Controlled Studies Reported in ≥ 2% of Canagliflozin-Treated Patients<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Rrule" align="center">Placebo<br>N=646</th>
<th class="Rrule" align="center">Canagliflozin<br>100 mg<br>N=833</th>
<th class="Rrule" align="center">Canagliflozin<br>300 mg<br>N=834</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The four placebo-controlled trials included one monotherapy trial and three add-on combination trials with metformin, metformin and sulfonylurea, or metformin and pioglitazone.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include the following adverse reactions: <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vulvovaginal candidiasis</span>, Vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal infection</span>, <span class="product-label-link" type="condition" conceptid="4269221" conceptname="Vulvitis">Vulvitis</span>, and <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">Genital infection</span> fungal. Percentages calculated with the number of female subjects in each group as denominator: placebo (N=312), canagliflozin 100 mg (N=425), and canagliflozin 300 mg (N=430).</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> include the following adverse reactions: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>, <span class="product-label-link" type="condition" conceptid="192964" conceptname="Infectious disorder of kidney">Kidney infection</span>, and <span class="product-label-link" type="condition" conceptid="4159744" conceptname="Urosepsis">Urosepsis</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Increased urination includes the following adverse reactions: <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span>, Urine output increased, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">Micturition urgency</span>, and <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include the following adverse reactions: <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanoposthitis</span>, <span class="product-label-link" type="condition" conceptid="4199600" conceptname="Candidal balanitis">Balanitis candida</span>, and <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">Genital infection</span> fungal. Percentages calculated with the number of male subjects in each group as denominator: placebo (N=334), canagliflozin 100 mg (N=408), and canagliflozin 300 mg (N=404).</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span> includes the following adverse reactions: <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">Polydipsia</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3.2%</td>
<td class="Rrule" align="center">10.4%</td>
<td class="Rrule" align="center">11.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">4.0%</td>
<td class="Rrule" align="center">5.9%</td>
<td class="Rrule" align="center">4.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Increased urination<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.8%</td>
<td class="Rrule" align="center">5.3%</td>
<td class="Rrule" align="center">4.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">0.6%</td>
<td class="Rrule" align="center">4.2%</td>
<td class="Rrule" align="center">3.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">Vulvovaginal pruritus</span></td>
<td class="Rrule" align="center">0.0%</td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">3.0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Rrule" align="center">0.2%</td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">2.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">0.9%</td>
<td class="Rrule" align="center">1.8%</td>
<td class="Rrule" align="center">2.3%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">2.3%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> was also more commonly reported in patients taking canagliflozin 100 mg (1.8%), 300 mg (1.7%) than in patients taking placebo (0.8%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin and Metformin</span></p>
<p>The incidence and type of adverse reactions in the three 26-week placebo-controlled metformin add-on studies, representing a majority of data from the four 26-week placebo-controlled trials, was similar to the adverse reactions described in Table 1. There were no additional adverse reactions identified in the pooling of these three placebo-controlled studies that included metformin relative to the four placebo-controlled studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.3"></a><p></p>
<p class="First"><span class="Italics">Pool of Placebo- and Active-Controlled Trials - Canagliflozin</span></p>
<p>The occurrence of adverse reactions for canagliflozin was evaluated in a larger pool of patients participating in placebo- and active-controlled trials.</p>
<p>The data combined eight clinical trials and reflect exposure of 6177 patients to canagliflozin. The mean duration of exposure to canagliflozin was 38 weeks with 1832 individuals exposed to canagliflozin for greater than 50 weeks. Patients received canagliflozin 100 mg (N=3092), canagliflozin 300 mg (N=3085) or comparator (N=3262) once daily. The mean age of the population was 60 years and 5% were older than 75 years of age. Fifty-eight percent (58%) of the population was male and 73% were Caucasian, 16% were Asian, and 4% were Black or African American. At baseline, the population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 11 years, had a mean HbA1C of 8.0% and 33% had established microvascular complications of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Baseline renal function was normal or mildly impaired (mean eGFR 81 mL/min/1.73 m<span class="Sup">2</span>).</p>
<p>The types and frequency of common adverse reactions observed in the pool of eight clinical trials were consistent with those listed in Table 1. In this pool, canagliflozin was also associated with the adverse reactions of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (1.7% with comparator, 2.2% with canagliflozin 100 mg, and 2.0% with canagliflozin 300 mg) and loss of strength or energy (i.e., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>) (0.6% with comparator, 0.7% with canagliflozin 100 mg, and 1.1% with canagliflozin 300 mg).</p>
<p>In the pool of eight clinical trials, the incidence rate of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (acute or chronic) was 0.9, 2.7, and 0.9 per 1000 patient-years of exposure to comparator, canagliflozin 100 mg, and canagliflozin 300 mg, respectively.</p>
<p>In the pool of eight clinical trials, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>-related adverse reactions (including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. Five patients experienced serious adverse reactions of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> with canagliflozin, which included 4 patients with <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and 1 patient with a diffuse <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> occurring within hours of exposure to canagliflozin. Among these patients, 2 patients discontinued canagliflozin. One patient with <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> had recurrence when canagliflozin was re-initiated.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>-related adverse reactions (including <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4080921" conceptname="Polymorphous light eruption">polymorphic light eruption</span>, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, canagliflozin 100 mg, and canagliflozin 300 mg, respectively.</p>
<p>Other adverse reactions occurring more frequently on canagliflozin than on comparator were:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span>-Related Adverse Reactions</span></p>
<p>Canagliflozin results in an osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, which may lead to reductions in intravascular volume. In clinical studies, treatment with canagliflozin was associated with a dose-dependent increase in the incidence of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>-related adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>). An increased incidence was observed in patients on the 300 mg dose. The three factors associated with the largest increase in <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>-related adverse reactions were the use of loop diuretics, moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span>), and age 75 years and older (Table 2) <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S5.2">Warnings and Precautions (5.2)</a>, and <a href="#S8.5">Use in Specific Populations (8.5)</a>, <a href="#S8.6"> (8.6)</a>]</span>.</p>
<table width="90%">
<caption><span>Table 2: Proportion of Patients With at Least One <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span>-Related Adverse Reaction (Pooled Results from 8 Clinical Trials)</span></caption>
<col align="left" valign="bottom" width="28%">
<col align="center" valign="bottom" width="22%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Baseline Characteristic</th>
<th class="Rrule" align="center">Comparator Group<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><br>%</th>
<th class="Rrule" align="center">Canagliflozin 100 mg<br>%</th>
<th class="Rrule" align="center">Canagliflozin 300 mg<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Includes placebo and active-comparator groups</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Patients could have more than 1 of the listed risk factors</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Overall population</td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">3.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">75 years of age and older<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2.6%</td>
<td class="Rrule" align="center">4.9%</td>
<td class="Rrule" align="center">8.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">eGFR less than 60 mL/min/1.73 m<span class="Sup">2</span><a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2.5%</td>
<td class="Rrule" align="center">4.7%</td>
<td class="Rrule" align="center">8.1%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Use of loop diuretic<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4.7%</td>
<td class="Rrule" align="center">3.2%</td>
<td class="Rrule" align="center">8.8%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.5"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falls</span></span></p>
<p>In a pool of nine clinical trials with mean duration of exposure to canagliflozin of 85 weeks, the proportion of patients who experienced <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> was 1.3%, 1.5%, and 2.1% with comparator, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. The higher risk of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> for patients treated with canagliflozin was observed within the first few weeks of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.6"></a><p></p>
<p class="First"><span class="Italics">Impairment in Renal Function</span></p>
<p>Canagliflozin is associated with a dose-dependent increase in serum creatinine and a concomitant <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in estimated GFR (Table 3). Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline had larger mean changes.</p>
<a name="table3"></a><table width="90%">
<caption><span>Table 3: Changes in Serum Creatinine and eGFR Associated with Canagliflozin in the Pool of Four Placebo-Controlled Trials and Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Trial</span></caption>
<col align="left" valign="middle" width="16%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Week 26 in mITT LOCF population</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" colspan="3"></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Placebo<br>N=646</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>N=833</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>N=834</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="6">Pool of Four Placebo-Controlled Trials</td>
<td class="Rrule" align="left" rowspan="2">Baseline</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">0.84</td>
<td class="Rrule" align="center" valign="bottom">0.82</td>
<td class="Rrule" align="center" valign="bottom">0.82</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">87.0</td>
<td class="Rrule" align="center" valign="bottom">88.3</td>
<td class="Rrule" align="center" valign="bottom">88.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">Week 6 Change</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">0.01</td>
<td class="Rrule" align="center" valign="bottom">0.03</td>
<td class="Rrule" align="center" valign="bottom">0.05</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">-1.6</td>
<td class="Rrule" align="center" valign="bottom">-3.8</td>
<td class="Rrule" align="center" valign="bottom">-5.0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">End of Treatment Change<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">0.01</td>
<td class="Rrule" align="center" valign="bottom">0.02</td>
<td class="Rrule" align="center" valign="bottom">0.03</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">-1.6</td>
<td class="Rrule" align="center" valign="bottom">-2.3</td>
<td class="Rrule" align="center" valign="bottom">-3.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="3"></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Placebo<br>N=90</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>N=90</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>N=89</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="6">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Trial</td>
<td class="Rrule" align="left" rowspan="2">Baseline</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">1.61</td>
<td class="Rrule" align="center" valign="bottom">1.62</td>
<td class="Rrule" align="center" valign="bottom">1.63</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">40.1</td>
<td class="Rrule" align="center" valign="bottom">39.7</td>
<td class="Rrule" align="center" valign="bottom">38.5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">Week 3 Change</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">0.03</td>
<td class="Rrule" align="center" valign="bottom">0.18</td>
<td class="Rrule" align="center" valign="bottom">0.28</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">-0.7</td>
<td class="Rrule" align="center" valign="bottom">-4.6</td>
<td class="Rrule" align="center" valign="bottom">-6.2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">End of Treatment Change<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="left">Creatinine (mg/dL)</td>
<td class="Rrule" align="center" valign="bottom">0.07</td>
<td class="Rrule" align="center" valign="bottom">0.16</td>
<td class="Rrule" align="center" valign="bottom">0.18</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</td>
<td class="Rrule" align="center" valign="bottom">-1.5</td>
<td class="Rrule" align="center" valign="bottom">-3.6</td>
<td class="Rrule" align="center" valign="bottom">-4.0</td>
</tr>
</tbody>
</table>
<p>In the pool of four placebo-controlled trials where patients had normal or mildly impaired baseline renal function, the proportion of patients who experienced at least one event of significant renal function decline, defined as an eGFR below 80 mL/min/1.73 m<span class="Sup">2</span> and 30% lower than baseline, was 2.1% with placebo, 2.0% with canagliflozin 100 mg, and 4.1% with canagliflozin 300 mg. At the end of treatment, 0.5% with placebo, 0.7% with canagliflozin 100 mg, and 1.4% with canagliflozin 300 mg had a significant renal function decline.</p>
<p>In a trial carried out in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with a baseline eGFR of 30 to less than 50 mL/min/1.73 m<span class="Sup">2</span> (mean baseline eGFR 39 mL/min/1.73 m<span class="Sup">2</span>), the proportion of patients who experienced at least one event of significant renal function decline, defined as an eGFR 30% lower than baseline, was 6.9% with placebo, 18% with canagliflozin 100 mg, and 22.5% with canagliflozin 300 mg. At the end of treatment, 4.6% with placebo, 3.4% with canagliflozin 100 mg, and 2.2% with canagliflozin 300 mg had a significant renal function decline.</p>
<p>In a pooled population of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (N=1085) with baseline eGFR of 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span> (mean baseline eGFR 48 mL/min/1.73 m<span class="Sup">2</span>), the overall incidence of these events was lower than in the dedicated trial but a dose-dependent increase in incident episodes of significant renal function decline compared to placebo was still observed. Use of canagliflozin has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>), particularly in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>In the pooled analysis of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the incidence of renal-related adverse reactions was 3.7% with placebo, 8.9% with canagliflozin 100 mg, and 9.3% with canagliflozin 300 mg. Discontinuations due to renal-related adverse events occurred in 1.0% with placebo, 1.2% with canagliflozin 100 mg, and 1.6% with canagliflozin 300 mg<span class="Italics"> [see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.7"></a><p></p>
<p class="First"><span class="Italics">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>In the pool of four placebo-controlled clinical trials, female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span>, and <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. Patients with a history of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more likely to develop genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> on canagliflozin. Female patients who developed genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> on canagliflozin were more likely to experience recurrence and require treatment with oral or topical antifungal agents and anti-microbial agents. In females, discontinuation due to genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred in 0% and 0.7% of patients treated with placebo and canagliflozin, respectively <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
<p>In the pool of four placebo-controlled clinical trials, male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., candidal <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred more commonly in uncircumcised males and in males with a prior history of <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>. Male patients who developed genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> on canagliflozin were more likely to experience recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (22% on canagliflozin versus none on placebo), and require treatment with oral or topical antifungal agents and anti-microbial agents than patients on comparators. In males, discontinuations due to genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred in 0% and 0.5% of patients treated with placebo and canagliflozin, respectively. In the pooled analysis of 8 controlled trials, <span class="product-label-link" type="condition" conceptid="4109633" conceptname="Congenital phimosis">phimosis</span> was reported in 0.3% of uncircumcised male patients treated with canagliflozin and 0.2% required circumcision to treat the <span class="product-label-link" type="condition" conceptid="4109633" conceptname="Congenital phimosis">phimosis</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.8"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>In canagliflozin clinical trials, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was defined as any event regardless of symptoms, where biochemical <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was documented (any glucose value below or equal to 70 mg/dL). Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was defined as an event consistent with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> where the patient required the assistance of another person to recover, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">lost consciousness</span>, or experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (regardless of whether biochemical documentation of a low glucose value was obtained). In individual clinical trials<span class="Italics"> [see <a href="#S14.6">Clinical Studies (14.6)</a>]</span>, episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurred at a higher rate when canagliflozin was co-administered with insulin or sulfonylureas (Table 4) <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
<a name="table4"></a><table width="90%">
<caption><span>Table 4: Incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a> in Controlled Clinical Studies</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="22%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last"><th align="left" colspan="4"></th></tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Number of patients experiencing at least one event of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> based on either biochemically documented episodes or severe hypoglycemic events in the intent-to-treat population</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>Severe episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were defined as those where the patient required the assistance of another person to recover, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">lost consciousness</span>, or experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (regardless of whether biochemical documentation of a low glucose value was obtained)</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>Phase 2 clinical study with twice daily dosing (50 mg or 150 mg twice daily in combination with metformin)</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">§</a></dt>
<dd>Subgroup of patients (N=287) from insulin substudy on canagliflozin in combination with metformin and insulin (with or without other antiglycemic agents)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Monotherapy<br>(26 weeks)</span></td>
<td class="Rrule" align="center"><span class="Bold">Placebo<br>(N=192)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>(N=195)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>(N=197)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">5 (2.6)</td>
<td class="Rrule" align="center">7 (3.6)</td>
<td class="Rrule" align="center">6 (3.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">In Combination with Metformin<br>(26 weeks)</span></td>
<td class="Rrule" align="center"><span class="Bold">Placebo + Metformin<br>(N=183)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg + Metformin<br>(N=368)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg + Metformin<br>(N=367)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">3 (1.6)</td>
<td class="Rrule" align="center">16 (4.3)</td>
<td class="Rrule" align="center">17 (4.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Severe [N (%)]<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0 (0)</td>
<td class="Rrule" align="center">1 (0.3)</td>
<td class="Rrule" align="center">1 (0.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">In Combination with Metformin <br>(18 weeks)</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"><span class="Bold">Placebo<br>(N=93)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>(N=93)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>(N=93)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">3 (3.2)</td>
<td class="Rrule" align="center">4 (4.3)</td>
<td class="Rrule" align="center">3 (3.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">In Combination with Metformin + Sulfonylurea<br>(26 weeks)</span></td>
<td class="Rrule" align="center"><span class="Bold">Placebo + Metformin + Sulfonylurea<br>(N=156)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg + Metformin + Sulfonylurea<br>(N=157)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg + Metformin + Sulfonylurea<br>(N=156)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">24 (15.4)</td>
<td class="Rrule" align="center">43 (27.4)</td>
<td class="Rrule" align="center">47 (30.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Severe [N (%)]<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">1 (0.6)</td>
<td class="Rrule" align="center">1 (0.6)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">In Combination with Metformin + Pioglitazone<br>(26 weeks)</span></td>
<td class="Rrule" align="center"><span class="Bold">Placebo + Metformin + Pioglitazone<br>(N=115)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg + Metformin + Pioglitazone<br>(N=113)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg + Metformin + Pioglitazone<br>(N=114)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">3 (2.6)</td>
<td class="Rrule" align="center">3 (2.7)</td>
<td class="Rrule" align="center">6 (5.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">In Combination with Insulin<br>(18 weeks)</span></td>
<td class="Rrule" align="center"><span class="Bold">Placebo<br>(N=565)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>(N=566)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>(N=587)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">208 (36.8)</td>
<td class="Rrule" align="center">279 (49.3)</td>
<td class="Rrule" align="center">285 (48.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Severe [N (%)]<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">14 (2.5)</td>
<td class="Rrule" align="center">10 (1.8)</td>
<td class="Rrule" align="center">16 (2.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">In Combination with Insulin and Metformin (18 weeks)</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">§</a>
</td>
<td class="Rrule" align="center"><span class="Bold">Placebo<br>(N=145)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 100 mg<br>(N=139)</span></td>
<td class="Rrule" align="center"><span class="Bold">Canagliflozin 300 mg<br>(N=148)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall [N (%)]</td>
<td class="Rrule" align="center">66 (45.5)</td>
<td class="Rrule" align="center">58 (41.7)</td>
<td class="Rrule" align="center">70 (47.3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Severe [N (%)]<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4 (2.8)</td>
<td class="Rrule" align="center">1 (0.7)</td>
<td class="Rrule" align="center">3 (2.0)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></span></p>
<p>The occurrence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> was evaluated in a pool of nine clinical trials with a mean duration of exposure to canagliflozin of 85 weeks. The incidence rates of adjudicated bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were 1.1, 1.4, and 1.5 per 100 patient-years of exposure in the comparator, canagliflozin 100 mg, and canagliflozin 300 mg groups, respectively. <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> were observed as early as 12 weeks after treatment initiation and were more likely to be low <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (e.g., <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> from no more than standing height), and affect the upper extremities <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First">Metformin</p>
<p>The most common adverse reactions (5% or greater incidence) due to initiation of metformin are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Long-term treatment with metformin has been associated with a decrease in vitamin B<span class="Sub">12</span>, which may very rarely result in clinically significant vitamin B<span class="Sub">12</span> deficiency (e.g., <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>) <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.1.4"></a><p></p>
<p class="First">Laboratory and Imaging Tests</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.1"></a><p></p>
<p class="First"><span class="Italics">Increases in Serum Potassium</span></p>
<p>In a pooled population of patients (N=723) with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span>), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. Severe elevations (greater than or equal to 6.5 mEq/L) occurred in 0.4% of patients treated with placebo, no patients treated with canagliflozin 100 mg, and 1.3% of patients treated with canagliflozin 300 mg.</p>
<p>In these patients, increases in potassium were more commonly seen in those with elevated potassium at baseline. Among patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, approximately 84% were taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, angiotensin-converting-enzyme inhibitors, and angiotensin-receptor blockers <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S5.4">(5.4)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.2"></a><p></p>
<p class="First"><span class="Italics">Increases in Serum Magnesium</span></p>
<p>Dose-related increases in serum magnesium were observed early after initiation of canagliflozin (within 6 weeks) and remained elevated throughout treatment. In the pool of four placebo-controlled trials, the mean percent change in serum magnesium levels was 8.1% and 9.3% with canagliflozin 100 mg and canagliflozin 300 mg, respectively, compared to -0.6% with placebo. In a trial of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, serum magnesium levels increased by 0.2%, 9.2%, and 14.8% with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.3"></a><p></p>
<p class="First"><span class="Italics">Increases in Serum Phosphate</span></p>
<p>Dose-related increases in serum phosphate levels were observed with canagliflozin. In the pool of four placebo-controlled trials, the mean percent change in serum phosphate levels were 3.6% and 5.1% with canagliflozin 100 mg and canagliflozin 300 mg, respectively, compared to 1.5% with placebo. In a trial of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the mean serum phosphate levels increased by 1.2%, 5.0%, and 9.3% with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.4"></a><p></p>
<p class="First"><span class="Italics">Increases in Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C) and non-High-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (non-HDL-C)</span></p>
<p>In the pool of four placebo-controlled trials, dose-related increases in LDL-C with canagliflozin were observed. Mean changes (percent changes) from baseline in LDL-C relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with canagliflozin 100 mg and canagliflozin 300 mg, respectively. The mean baseline LDL-C levels were 104 to 110 mg/dL across treatment groups <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>.</p>
<p>Dose-related increases in non-HDL-C with canagliflozin were observed. Mean changes (percent changes) from baseline in non-HDL-C relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with canagliflozin 100 mg and 300 mg, respectively. The mean baseline non-HDL-C levels were 140 to 147 mg/dL across treatment groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.5"></a><p></p>
<p class="First"><span class="Italics">Increases in Hemoglobin</span></p>
<p>In the pool of four placebo-controlled trials, mean changes (percent changes) from baseline in hemoglobin were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with canagliflozin 100 mg, and 0.51 g/dL (3.8%) with canagliflozin 300 mg. The mean baseline hemoglobin value was approximately 14.1 g/dL across treatment groups. At the end of treatment, 0.8%, 4.0%, and 2.7% of patients treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively, had hemoglobin levels above the upper limit of normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.6"></a><p></p>
<p class="First"><span class="Italics">Decreases in Bone Mineral Density</span></p>
<p>Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry in a clinical trial of 714 older adults (mean age 64 years). At 2 years, patients randomized to canagliflozin 100 mg and canagliflozin 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively. Additionally, placebo-adjusted BMD declines were 0.1% at the femoral neck for both canagliflozin doses and 0.4% at the distal forearm for patients randomized to canagliflozin 300 mg. The placebo-adjusted change at the distal forearm for patients randomized to canagliflozin 100 mg was 0%.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Drug Interactions with Metformin</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Underline">Cationic Drugs</span></p>
<p>Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of INVOKAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Underline">Carbonic Anhydrase Inhibitors</span></p>
<p>Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently decrease serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and induce non-<span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, hyperchloremic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Concomitant use of these drugs may induce <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and may increase the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> when these drugs are used concomitantly with INVOKAMET <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<p class="First"><span class="Underline">Drugs Affecting Glycemic Control</span></p>
<p>Certain drugs tend to produce <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. When such drugs are administered to a patient receiving INVOKAMET, monitor for loss of blood glucose control. When such drugs are withdrawn from a patient receiving INVOKAMET, monitor for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drug Interactions with Canagliflozin</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Underline">UGT Enzyme Inducers</span></p>
<p>Rifampin: Rifampin lowered canagliflozin exposure which may reduce the efficacy of INVOKAMET. If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) must be co-administered with INVOKAMET, consider increasing the dose to canagliflozin 150 mg twice daily if patients are currently tolerating INVOKAMET with 50 mg canagliflozin twice daily, have an eGFR greater than 60 mL/min/1.73 m<span class="Sup">2</span>, and require additional glycemic control. Consider other antihyperglycemic therapy in patients with an eGFR of 45 to less than 60 mL/min/1.73 m<span class="Sup">2</span> receiving concurrent therapy with a UGT inducer and require additional glycemic control <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Underline">Digoxin</span></p>
<p>Canagliflozin increased digoxin exposure. Digoxin, as a cationic drug, also has the potential to compete with metformin for common renal tubular transport systems <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. Monitor patients taking INVOKAMET with concomitant digoxin for a need to adjust dose of either drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Underline">Drug/Laboratory Test Interference</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3.1"></a><p></p>
<p class="First"><span class="Italics">Positive Urine Glucose Test</span></p>
<p>Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3.2"></a><p></p>
<p class="First"><span class="Italics">Interference with 1,5-anhydroglucitol (1,5-AG) Assay</span></p>
<p>Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Teratogenic Effects</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First">Pregnancy Category C:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>There are no adequate and well-controlled studies in pregnant women with INVOKAMET or its individual components. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters. INVOKAMET should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1.2"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Based on results from rat studies, canagliflozin may affect renal development and maturation. In a juvenile rat study, increased kidney weights and renal pelvic and tubular dilatation were evident at greater than or equal to 0.5 times clinical exposure from a 300 mg dose <span class="Italics">[see <a href="#S13.2">Nonclinical Toxicology (13.2)</a>]</span>.</p>
<p>These outcomes occurred with drug exposure during periods of animal development that correspond to the late second and third trimester of human development.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1.3"></a><p></p>
<p class="First">Metformin</p>
<p>Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>No studies in lactating animals have been conducted with the combined components of INVOKAMET.</p>
<p>Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from INVOKAMET, a decision should be made whether to discontinue nursing or to discontinue INVOKAMET, taking into account the importance of the drug to the mother <span class="Italics">[see <a href="#S13.2">Nonclinical Toxicology (13.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.2"></a><p></p>
<p class="First">Canagliflozin</p>
<p>It is not known if canagliflozin is excreted in human milk. Canagliflozin is secreted in the milk of lactating rats reaching levels 1.4 times higher than that in maternal plasma. Data in juvenile rats directly exposed to canagliflozin showed risk to the developing kidney (renal pelvic and tubular dilatations) during maturation. Since human kidney maturation occurs <span class="Italics">in utero</span> and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.3"></a><p></p>
<p class="First">Metformin</p>
<p>Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. It is not known whether metformin is secreted in human milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of INVOKAMET in pediatric patients under 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>Because renal function abnormalities can occur after initiating canagliflozin, metformin is substantially excreted by the kidney, and aging can be associated with reduced renal function, monitor renal function more frequently after initiating INVOKAMET in the elderly and then adjust dose based on renal function <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S5.3">(5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Two thousand thirty-four (2034) patients 65 years and older, and 345 patients 75 years and older were exposed to canagliflozin in nine clinical studies of canagliflozin. Of these patients, 1334 patients 65 years and older and 181 patients 75 years and older were exposed to the combination of canagliflozin and metformin <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. Patients 65 years and older had a higher incidence of adverse reactions related to reduced intravascular volume with canagliflozin (such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>), particularly with the 300 mg daily dose, compared to younger patients; a more prominent increase in the incidence was seen in patients who were 75 years and older <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>].</span> Smaller reductions in HbA1C with canagliflozin relative to placebo were seen in older (65 years and older; -0.61% with canagliflozin 100 mg and -0.74% with canagliflozin 300 mg relative to placebo) compared to younger patients (-0.72% with canagliflozin 100 mg and -0.87% with canagliflozin 300 mg relative to placebo).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.3"></a><p></p>
<p class="First">Metformin</p>
<p>Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. The initial and maintenance dosing of metformin should be conservative in patients with advanced age due to the potential for decreased renal function in this population. Any dose adjustment should be based on a careful assessment of renal function <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>The efficacy and safety of canagliflozin were evaluated in a study that included patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 50 mL/min/1.73 m<span class="Sup">2</span>). These patients had less overall glycemic efficacy and had a higher occurrence of adverse reactions related to reduced intravascular volume, renal-related adverse reactions, and decreases in eGFR compared to patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or normal renal function (eGFR greater than or equal to 60 mL/min/1.73 m<span class="Sup">2</span>). Dose-related, transient mean increases in serum potassium were observed early after initiation of canagliflozin (i.e., within 3 weeks) in this trial. Increases in serum potassium of greater than 5.4 mEq/L and 15% above baseline occurred in 16.1%, 12.4%, and 27.0% of patients treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively. Severe elevations (greater than or equal to 6.5 mEq/L) occurred in 1.1%, 2.2%, and 2.2% of patients treated with placebo, canagliflozin 100 mg, and canagliflozin 300 mg, respectively <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a>, <a href="#s4">Contraindications (4)</a>, <a href="#s5.2">Warnings and Precautions (5.2)</a>, <a href="#s5.3">(5.3)</a>, <a href="#s5.4">(5.4)</a>, and <a href="#s6.1">Adverse Reactions (6.1)</a>].</span></p>
<p>The efficacy and safety of canagliflozin have not been established in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR less than 30 mL/min/1.73 m<span class="Sup">2</span>), with ESRD, or receiving dialysis. Canagliflozin is not expected to be effective in these patient populations <span class="Italics">[see <a href="#s4">Contraindications (4)</a> and <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with INVOKAMET, contact the Poison Control Center. Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient's clinical status. Canagliflozin was negligibly removed during a 4-hour hemodialysis session. Canagliflozin is not expected to be dialyzable by peritoneal dialysis. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful partly for removal of accumulated metformin from patients in whom INVOKAMET overdosage is suspected.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>There were no reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> during the clinical development program of canagliflozin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First">Metformin</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> has been reported in approximately 32% of metformin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">INVOKAMET (canagliflozin and metformin hydrochloride) tablets contain two oral antihyperglycemic drugs used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: canagliflozin and metformin hydrochloride.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Canagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. Canagliflozin is chemically known as (1<span class="Italics">S</span>)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and its molecular formula and weight are C<span class="Sub">24</span>H<span class="Sub">25</span>FO<span class="Sub">5</span>S∙1/2 H<span class="Sub">2</span>O and 453.53, respectively. The structural formula for canagliflozin is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-01.jpg"></div>
<p>Canagliflozin is practically insoluble in aqueous media from pH 1.1 to 12.9.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<p class="First">Metformin Hydrochloride</p>
<p>Metformin hydrochloride is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is chemically known as 1,1-Dimethylbiguanide hydrochloride and its molecular formula and weight are C<span class="Sub">4</span>H<span class="Sub">11</span>N<span class="Sub">5 </span>∙ HCl and 165.62, respectively. The structural formula for metformin hydrochloride is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<p class="First">INVOKAMET</p>
<p>INVOKAMET is supplied as film-coated tablets for oral administration. Each 50 mg/500 mg tablet and 50 mg/1,000 mg tablet contains 51 mg of canagliflozin equivalent to 50 mg canagliflozin (anhydrous) and 500 mg or 1,000 mg metformin hydrochloride. Each 150 mg/500 mg tablet and 150 mg/1,000 mg tablet contains 153 mg of canagliflozin equivalent to 150 mg canagliflozin (anhydrous) and 500 mg or 1,000 mg metformin hydrochloride.</p>
<p>Inactive ingredients of the core tablet are croscarmellose sodium, hypromellose, magnesium stearate, and microcrystalline cellulose. The magnesium stearate is vegetable-sourced. The tablets are finished with a commercially available film-coating consisting of the following excipients: Macrogol/PEG, polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, iron oxide yellow, (50 mg/1,000 mg and 150 mg/500 mg tablets only), iron oxide red, (50 mg/1,000 mg, 150 mg/500 mg and 150 mg/1,000 mg tablets only), and iron oxide black (150 mg/1,000 mg tablets only).</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>INVOKAMET (canagliflozin and metformin hydrochloride) combines two oral antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a member of the biguanide class.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT<span class="Sub">G</span>), and thereby increases urinary glucose excretion (UGE).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.3"></a><p></p>
<p class="First">Metformin</p>
<p>Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin does not produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in either patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or normal subjects except in special circumstances <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span> and does not cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span>. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>Following single and multiple oral doses of canagliflozin in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, dose-dependent decreases in RT<span class="Sub">G</span> and increases in urinary glucose excretion were observed. From a starting RT<span class="Sub">G</span> value of approximately 240 mg/dL, canagliflozin at 100 mg and 300 mg once daily suppressed RT<span class="Sub">G</span> throughout the 24-hour period. Maximal suppression of mean RT<span class="Sub">G</span> over the 24-hour period was seen with the 300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in Phase 1 studies. The reductions in RT<span class="Sub">G</span> led to increases in mean UGE of approximately 100 g/day in subjects with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treated with either 100 mg or 300 mg of canagliflozin. The 24-h mean RT<span class="Sub">G</span> at steady state was similar following once daily and twice daily dosing regimens at the same total daily dose of 100 mg or 300 mg. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> given 100 to 300 mg once daily over a 16-day dosing period, reductions in RT<span class="Sub">G</span> and increases in urinary glucose excretion were observed over the dosing period. In this study, plasma glucose declined in a dose-dependent fashion within the first day of dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First">Cardiac Electrophysiology</p>
<p>In a randomized, double-blind, placebo-controlled, active-comparator, 4-way crossover study, 60 healthy subjects were administered a single oral dose of canagliflozin 300 mg, canagliflozin 1,200 mg (4 times the maximum recommended dose), moxifloxacin, and placebo. No meaningful changes in QTc interval were observed with either the recommended dose of 300 mg or the 1,200 mg dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>The results of a bioequivalence study in healthy subjects demonstrated that INVOKAMET 50 mg/500 mg, 50 mg/1,000 mg, 150 mg/500 mg and 150 mg/1,000 mg combination tablets are bioequivalent to co-administration of corresponding doses of canagliflozin and metformin hydrochloride as individual tablets under fed conditions.</p>
<p>Administration of INVOKAMET 150 mg/1,000 mg fixed-dose combination with food resulted in no change in overall exposure of canagliflozin. There was no change in metformin AUC; however, the mean peak plasma concentration of metformin was decreased by 16% when administered with food. A delayed time to peak plasma concentration was observed for both components (a delay of 2 hours for canagliflozin and 1 hour for metformin) under fed conditions. These changes are not likely to be clinically meaningful.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p>The pharmacokinetics of canagliflozin is essentially similar in healthy subjects and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Following single-dose oral administration of 100 mg and 300 mg of canagliflozin, peak plasma concentrations (median T<span class="Sub">max</span>) of canagliflozin occurs within 1 to 2 hours post-dose. Plasma C<span class="Sub">max</span> and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. The apparent terminal half-life (t<span class="Sub">1/2</span>) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively. Steady-state was reached after 4 to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg. Canagliflozin does not exhibit time-dependent pharmacokinetics and accumulated in plasma up to 36% following multiple doses of 100 mg and 300 mg. The mean systemic exposure (AUC) at steady state was similar following once daily and twice daily dosing regimens at the same total daily dose of 100 mg or 300 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First">Absorption</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p>The mean absolute oral bioavailability of canagliflozin is approximately 65%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.2"></a><p></p>
<p class="First"><span class="Italics">Metformin</span></p>
<p>The absolute bioavailability of a metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin hydrochloride 500 to 1,500 mg, and 850 to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First">Distribution</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p>The mean steady-state volume of distribution of canagliflozin following a single intravenous infusion in healthy subjects was 119 L, suggesting extensive tissue distribution. Canagliflozin is extensively bound to proteins in plasma (99%), mainly to albumin. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Italics">Metformin</span></p>
<p>The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride 850 mg tablets averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin tablets, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally less than 1 mcg/mL. During controlled clinical trials of metformin, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First">Metabolism</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p><span class="Italics">O</span>-glucuronidation is the major metabolic elimination pathway for canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive <span class="Italics">O</span>-glucuronide metabolites. CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Italics">Metformin</span></p>
<p>Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First">Excretion</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<p>Following administration of a single oral [<span class="Sup">14</span>C] canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in feces as canagliflozin, a hydroxylated metabolite, and an <span class="Italics">O</span>-glucuronide metabolite, respectively. Enterohepatic circulation of canagliflozin was negligible.</p>
<p>Approximately 33% of the administered radioactive dose was excreted in urine, mainly as <span class="Italics">O</span>−glucuronide metabolites (30.5%). Less than 1% of the dose was excreted as unchanged canagliflozin in urine. Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.</p>
<p>Mean systemic clearance of canagliflozin was approximately 192 mL/min in healthy subjects following intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Metformin</span></p>
<p>Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> may be a compartment of distribution.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First">Specific Populations</p>
<p>Studies characterizing the pharmacokinetics of canagliflozin and metformin after administration of INVOKAMET were not conducted in patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Descriptions of the individual components in this patient population are described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1.1"></a><p></p>
<p class="First"><span class="Underline">Canagliflozin</span></p>
<p>A single-dose, open-label study evaluated the pharmacokinetics of canagliflozin 200 mg in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (classified using the MDRD-eGFR formula) compared to healthy subjects.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> did not affect the C<span class="Sub">max</span> of canagliflozin. Compared to healthy subjects (N=3; eGFR greater than or equal to 90 mL/min/1.73 m<span class="Sup">2</span>), plasma AUC of canagliflozin was increased by approximately 15%, 29%, and 53% in subjects with mild (N=10), moderate (N=9), and severe (N=10) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively, (eGFR 60 to less than 90, 30 to less than 60, and 15 to less than 30 mL/min/1.73 m<span class="Sup">2</span>, respectively) but was similar for ESRD (N=8) subjects and healthy subjects. Increases in canagliflozin AUC of this magnitude are not considered clinically relevant. The pharmacodynamic response to canagliflozin declines with increasing severity of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
<p>Canagliflozin was negligibly removed by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1.2"></a><p></p>
<p class="First"><span class="Underline">Metformin</span></p>
<p>In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2.1"></a><p></p>
<p class="First"><span class="Underline">Canagliflozin</span></p>
<p>Relative to subjects with normal hepatic function, the geometric mean ratios for C<span class="Sub">max</span> and AUC<span class="Sub">∞</span> of canagliflozin were 107% and 110%, respectively, in subjects with Child-Pugh class A (mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>) and 96% and 111%, respectively, in subjects with Child-Pugh class B (moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>) following administration of a single 300 mg dose of canagliflozin.</p>
<p>These differences are not considered to be clinically meaningful. There is no clinical experience in patients with Child-Pugh class C (severe) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2.2"></a><p></p>
<p class="First"><span class="Underline">Metformin</span></p>
<p>No pharmacokinetic studies of metformin have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3"></a><p></p>
<p class="First"><span class="Italics">Pharmacokinetic Effects of Age, Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI)/Weight, Gender and Race</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3.1"></a><p></p>
<p class="First"><span class="Underline">Canagliflozin</span></p>
<p>Based on the population PK analysis with data collected from 1526 subjects, age, body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI)/weight, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of canagliflozin <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3.2"></a><p></p>
<p class="First"><span class="Underline">Metformin</span></p>
<p>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> when analyzed according to gender.</p>
<p>No studies of metformin pharmacokinetic parameters according to race have been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4"></a><p></p>
<p class="First"><span class="Italics">Geriatric</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4.1"></a><p></p>
<p class="First"><span class="Underline">INVOKAMET</span></p>
<p>Studies characterizing the pharmacokinetics of canagliflozin and metformin after administration of INVOKAMET in geriatric patients have not been performed <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S5.3">(5.3)</a> and <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4.2"></a><p></p>
<p class="First"><span class="Underline">Canagliflozin</span></p>
<p>Age had no clinically meaningful effect on the pharmacokinetics of canagliflozin based on a population pharmacokinetic analysis <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a> and <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4.3"></a><p></p>
<p class="First"><span class="Underline">Metformin</span></p>
<p>Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C<span class="Sub">max</span> is increased, compared with healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.5"></a><p></p>
<p class="First"><span class="Italics">Pediatric</span></p>
<p>Studies characterizing the pharmacokinetics of canagliflozin and metformin after administration of INVOKAMET in pediatric patients have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First">Drug-Drug Interactions</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.1"></a><p></p>
<p class="First"><span class="Italics">INVOKAMET</span></p>
<p>Pharmacokinetic drug interaction studies with INVOKAMET have not been performed; however, such studies have been conducted with the individual components canagliflozin and metformin hydrochloride.</p>
<p>Co-administration of multiple doses of canagliflozin (300 mg) and metformin (2,000 mg) given once daily did not meaningfully alter the pharmacokinetics of either canagliflozin or metformin in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2"></a><p></p>
<p class="First"><span class="Italics">Canagliflozin</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2.1"></a><p></p>
<p class="First"><span class="Italics Underline">In Vitro</span><span class="Underline"> Assessment of Drug Interactions</span></p>
<p>Canagliflozin did not induce CYP450 enzyme expression (3A4, 2C9, 2C19, 2B6, and 1A2) in cultured human hepatocytes. Canagliflozin did not inhibit the CYP450 isoenzymes (1A2, 2A6, 2C19, 2D6, or 2E1) and weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on <span class="Italics">in vitro </span>studies with human hepatic microsomes. Canagliflozin is a weak inhibitor of P-gp.</p>
<p>Canagliflozin is also a substrate of drug transporters P-glycoprotein (P-gp) and MRP2.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2.2"></a><p></p>
<p class="First"><span class="Italics Underline">In Vivo</span><span class="Underline"> Assessment of Drug Interactions</span></p>
<table width="90%">
<caption><span>Table 5: Effect of Co−Administered  Drugs on Systemic Exposures of Canagliflozin</span></caption>
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Co-Administered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Co-Administered  Drug<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">Dose of  Canagliflozin<a href="#footnote-14" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="3">Geometric Mean  Ratio <br>(Ratio  With/Without Co-Administered Drug)<br>No Effect = 1.0</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a><br>(90% CI)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span><br>(90% CI)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5" valign="top">QD = once daily; BID = twice daily</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Single dose unless otherwise noted</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>AUC<span class="Sub">inf</span> for drugs given as a single dose and AUC<span class="Sub">24h</span> for drugs given as multiple doses</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5">
<span class="Bold Italics">See <a href="#S7.2">Drug Interactions  (7.2)</a></span><span class="Bold"> for the clinical relevance of the  following:</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifampin</td>
<td class="Rrule" align="center">600 mg QD for 8 days</td>
<td class="Rrule" align="center">300 mg</td>
<td class="Rrule" align="center">0.49<br>(0.44; 0.54)</td>
<td class="Rrule" align="center">0.72<br>(0.61; 0.84)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">No dose adjustments of canagliflozin required for the  following:</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cyclosporine</td>
<td class="Rrule" align="center">400 mg</td>
<td class="Rrule" align="center">300 mg QD for 8 days</td>
<td class="Rrule" align="center">1.23<br>(1.19; 1.27)</td>
<td class="Rrule" align="center">1.01<br>(0.91; 1.11)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ethinyl estradiol and levonorgestrel</td>
<td class="Rrule" align="center">0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel</td>
<td class="Rrule" align="center">200 mg QD for 6 days</td>
<td class="Rrule" align="center">0.91<br>(0.88; 0.94)</td>
<td class="Rrule" align="center">0.92<br>(0.84; 0.99)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hydrochlorothiazide</td>
<td class="Rrule" align="center">25 mg QD for 35 days</td>
<td class="Rrule" align="center">300 mg QD for 7 days</td>
<td class="Rrule" align="center">1.12<br>(1.08; 1.17)</td>
<td class="Rrule" align="center">1.15<br>(1.06; 1.25)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metformin</td>
<td class="Rrule" align="center">2,000 mg</td>
<td class="Rrule" align="center">300 mg QD for 8 days</td>
<td class="Rrule" align="center">1.10<br>(1.05; 1.15)</td>
<td class="Rrule" align="center">1.05<br>(0.96; 1.16)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Probenecid</td>
<td class="Rrule" align="center">500 mg BID for 3 days</td>
<td class="Rrule" align="center">300 mg QD for 17 days</td>
<td class="Rrule" align="center">1.21<br>(1.16; 1.25)</td>
<td class="Rrule" align="center">1.13<br>(1.00; 1.28)</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="90%">
<caption><span>Table 6: Effect of Canagliflozin on  Systemic Exposure of Co-Administered Drugs</span></caption>
<col align="left" valign="middle" width="19%">
<col align="left" valign="middle" width="19%">
<col align="left" valign="middle" width="18%">
<col align="left" valign="middle" width="18%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Co-Administered  Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Co-Administered  Drug<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">Dose of  Canagliflozin<a href="#footnote-16" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="3">Geometric Mean  Ratio<br>(Ratio With/Without Co-Administered  Drug)<br>No Effect =  1.0</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">AUC<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a><br>(90% CI)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span><br>(90% CI)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6" valign="top">QD = once daily; BID = twice daily; INR = International Normalized Ratio</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Single dose unless otherwise noted</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>AUC<span class="Sub">inf</span> for drugs given as a single dose and AUC<span class="Sub">24h</span> for drugs given as multiple doses</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">‡</a></dt>
<dd>AUC<span class="Sub">0–12h</span>
</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="6"><span class="Bold"><span class="Italics">See <a href="#S7.2">Drug Interactions (7.2)</a></span> for the clinical relevance of the following:</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Digoxin</td>
<td class="Rrule" align="left">0.5 mg QD first day followed by 0.25 mg QD for 6 days</td>
<td class="Rrule" align="left">300 mg QD for 7 days</td>
<td class="Rrule" align="left">digoxin</td>
<td class="Rrule" align="center">1.20<br>(1.12; 1.28)</td>
<td class="Rrule" align="center">1.36<br>(1.21; 1.53)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="6"><span class="Bold">No dose adjustments of co-administered drug required for the following:</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Acetaminophen</td>
<td class="Rrule" align="left">1,000 mg</td>
<td class="Rrule" align="left">300 mg BID for 25 days</td>
<td class="Rrule" align="left">acetaminophen</td>
<td class="Rrule" align="center">1.06<a name="footnote-reference-18" href="#footnote-18" class="Sup">‡</a><br>(0.98; 1.14)</td>
<td class="Rrule" align="center">1.00<br>(0.92; 1.09)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Ethinyl estradiol and levonorgestrel</td>
<td class="Rrule" align="left" rowspan="2">0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel</td>
<td class="Rrule" align="left" rowspan="2">200 mg QD for 6 days</td>
<td class="Rrule" align="left">ethinyl estradiol</td>
<td class="Rrule" align="center">1.07<br>(0.99; 1.15)</td>
<td class="Rrule" align="center">1.22<br>(1.10; 1.35)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">levonorgestrel</td>
<td class="Rrule" align="center">1.06<br>(1.00; 1.13)</td>
<td class="Rrule" align="center">1.22<br>(1.11; 1.35)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Glyburide</td>
<td class="Rrule" align="left" rowspan="3">1.25 mg</td>
<td class="Rrule" align="left" rowspan="3">200 mg QD for 6 days</td>
<td class="Rrule" align="left">glyburide</td>
<td class="Rrule" align="center">1.02<br>(0.98; 1.07)</td>
<td class="Rrule" align="center">0.93<br>(0.85; 1.01)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">3-cis-hydroxy-glyburide</td>
<td class="Rrule" align="center">1.01<br>(0.96; 1.07)</td>
<td class="Rrule" align="center">0.99<br>(0.91; 1.08)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">4-trans-hydroxy-glyburide</td>
<td class="Rrule" align="center">1.03<br>(0.97; 1.09)</td>
<td class="Rrule" align="center">0.96<br>(0.88; 1.04)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hydrochlorothiazide</td>
<td class="Rrule" align="left">25 mg QD for 35 days</td>
<td class="Rrule" align="left">300 mg QD for 7 days</td>
<td class="Rrule" align="left">Hydrochloro-thiazide</td>
<td class="Rrule" align="center">0.99<br>(0.95; 1.04)</td>
<td class="Rrule" align="center">0.94<br>(0.87; 1.01)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metformin</td>
<td class="Rrule" align="left">2,000 mg</td>
<td class="Rrule" align="left">300 mg QD for 8 days</td>
<td class="Rrule" align="left">metformin</td>
<td class="Rrule" align="center">1.20<br>(1.08; 1.34)</td>
<td class="Rrule" align="center">1.06<br>(0.93; 1.20)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Simvastatin</td>
<td class="Rrule" align="left" rowspan="2">40 mg</td>
<td class="Rrule" align="left" rowspan="2">300 mg QD for 7 days</td>
<td class="Rrule" align="left">simvastatin</td>
<td class="Rrule" align="center">1.12<br>(0.94; 1.33)</td>
<td class="Rrule" align="center">1.09<br>(0.91; 1.31)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">simvastatin acid</td>
<td class="Rrule" align="center">1.18<br>(1.03; 1.35)</td>
<td class="Rrule" align="center">1.26<br>(1.10; 1.45)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Warfarin</td>
<td class="Rrule" align="left" rowspan="3">30 mg</td>
<td class="Rrule" align="left" rowspan="3">300 mg QD for 12 days</td>
<td class="Rrule" align="left">(R)-warfarin</td>
<td class="Rrule" align="center">1.01<br>(0.96; 1.06)</td>
<td class="Rrule" align="center">1.03<br>(0.94; 1.13)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">(S)-warfarin</td>
<td class="Rrule" align="center">1.06<br>(1.00; 1.12)</td>
<td class="Rrule" align="center">1.01<br>(0.90; 1.13)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">INR</td>
<td class="Rrule" align="center">1.00<br>(0.98; 1.03)</td>
<td class="Rrule" align="center">1.05<br>(0.99; 1.12)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.3"></a><p></p>
<p class="First"><span class="Italics">Metformin</span></p>
<a name="table7"></a><table width="90%">
<caption><span>Table 7: Effect of Co−Administered  Drugs on Plasma Metformin Systemic Exposures</span></caption>
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Co-Administered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Co-Administered  Drug<a name="footnote-reference-19" href="#footnote-19" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">Dose of Metformin<a href="#footnote-19" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">Geometric Mean  Ratio<br>(Ratio  With/Without Co-Administered Drug)<br>No Effect = 1.00</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC<a name="footnote-reference-20" href="#footnote-20" class="Sup">†</a>
</th>
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-19" href="#footnote-reference-19">*</a></dt>
<dd>Single dose unless otherwise noted</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">†</a></dt>
<dd>AUC = AUC<span class="Sub">0–∞</span>
</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">‡</a></dt>
<dd>Metformin hydrochloride extended-release tablets 500 mg</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">§</a></dt>
<dd>Ratio of arithmetic means</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">¶</a></dt>
<dd>Healthy volunteer study at steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours for 7 days. Study conducted to assess pharmacokinetics only</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">#</a></dt>
<dd>Steady state AUC<span class="Sub">0–12h</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">No dose adjustments required for the following:</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Glyburide</td>
<td class="Rrule" align="center">5 mg</td>
<td class="Rrule" align="center">500 mg<a name="footnote-reference-21" href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.98<a name="footnote-reference-22" href="#footnote-22" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.99<a href="#footnote-22" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Furosemide</td>
<td class="Rrule" align="center">40 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.09<a href="#footnote-22" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.22<a href="#footnote-22" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nifedipine</td>
<td class="Rrule" align="center">10 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.16</td>
<td class="Rrule" align="center">1.21</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Propranolol</td>
<td class="Rrule" align="center">40 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">0.90</td>
<td class="Rrule" align="center">0.94</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="center">400 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.05<a href="#footnote-22" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.07<a href="#footnote-22" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">
<span class="Bold">Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination: use with caution </span><span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a> and <a href="#S7">Drug Interactions (7)</a>]</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cimetidine</td>
<td class="Rrule" align="center">400 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.40</td>
<td class="Rrule" align="center">1.61</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">
<span class="Bold">Carbonic anhydrase inhibitors may cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>: use with caution </span><span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a> and <a href="#S7">Drug Interactions (7)</a>]</span>
</td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Topiramate<a name="footnote-reference-23" href="#footnote-23" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">100 mg</td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">1.25<a name="footnote-reference-24" href="#footnote-24" class="Sup">#</a>
</td>
<td class="Rrule" align="center">1.18</td>
</tr>
</tbody>
</table>
<table width="90%">
<caption><span>Table 8:	Effect of Metformin on Co−Administered Drug Systemic Exposures</span></caption>
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Co-Administered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Co-Administered  Drug<a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">Dose of Metformin<a href="#footnote-25" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">Geometric Mean  Ratio<br>(Ratio  With/Without Co-Administered Drug)<br>No Effect = 1.00</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC<a name="footnote-reference-26" href="#footnote-26" class="Sup">†</a>
</th>
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>Single dose unless otherwise noted</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">†</a></dt>
<dd>AUC = AUC<span class="Sub">0–∞</span>
</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">‡</a></dt>
<dd>AUC<span class="Sub">0–24 hr</span> reported</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">§</a></dt>
<dd>Ratio of arithmetic means, p-value of difference &lt;0.05</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">¶</a></dt>
<dd>Ratio of arithmetic means.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">No dose adjustments required for the following:</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Glyburide</td>
<td class="Rrule" align="center">5 mg</td>
<td class="Rrule" align="center">500 mg<a name="footnote-reference-27" href="#footnote-27" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.78<a name="footnote-reference-28" href="#footnote-28" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.63<a href="#footnote-28" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Furosemide</td>
<td class="Rrule" align="center">40 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">0.87<a href="#footnote-28" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.69<a href="#footnote-28" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nifedipine</td>
<td class="Rrule" align="center">10 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.10<a href="#footnote-27" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.08</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Propranolol</td>
<td class="Rrule" align="center">40 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">1.01<a href="#footnote-27" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.94</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="center">400 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">0.97<a name="footnote-reference-29" href="#footnote-29" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">1.01<a href="#footnote-29" class="Sup">¶</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Cimetidine</td>
<td class="Rrule" align="center">400 mg</td>
<td class="Rrule" align="center">850 mg</td>
<td class="Rrule" align="center">0.95<a href="#footnote-27" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.01</td>
</tr>
</tbody>
</table>
<p>Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First">INVOKAMET</p>
<p>No animal studies have been conducted with the combined products in INVOKAMET to evaluate carcinogenesis, mutagenesis, or impairment of fertility. The following data are based on findings in studies with canagliflozin and metformin individually.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First">Canagliflozin</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>Carcinogenicity was evaluated in 2-year studies conducted in CD1 mice and Sprague-Dawley rats. Canagliflozin did not increase the incidence of tumors in mice dosed at 10, 30, or 100 mg/kg (less than or equal to 14 times exposure from a 300 mg clinical dose).</p>
<p>Testicular Leydig cell tumors, considered secondary to increased luteinizing hormone (LH), increased significantly in male rats at all doses tested (10, 30, and 100 mg/kg). In a 12-week clinical study, LH did not increase in males treated with canagliflozin.</p>
<p>Renal tubular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and carcinoma increased significantly in male and female rats dosed at 100 mg/kg, or approximately 12-times exposure from a 300 mg clinical dose. Also, adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> increased significantly in males and numerically in females dosed at 100 mg/kg. Carbohydrate <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> associated with high doses of canagliflozin was considered a necessary proximal event in the emergence of renal and adrenal tumors in rats. Clinical studies have not demonstrated carbohydrate <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> in humans at canagliflozin doses of up to 2-times the recommended clinical dose of 300 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span></p>
<p>Canagliflozin was not mutagenic with or without metabolic activation in the Ames assay. Canagliflozin was mutagenic in the <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay with but not without metabolic activation. Canagliflozin was not mutagenic or clastogenic in an <span class="Italics">in vivo</span> oral micronucleus assay in rats and an <span class="Italics">in vivo</span> oral Comet assay in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span></p>
<p>Canagliflozin had no effects on the ability of rats to mate and sire or maintain a litter up to the high dose of 100 mg/kg (approximately 14 times and 18 times the 300 mg clinical dose in males and females, respectively), although there were minor alterations in a number of reproductive parameters (decreased sperm velocity, increased number of abnormal sperm, slightly fewer corpora lutea, fewer implantation sites, and smaller litter sizes) at the highest dosage administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First">Metformin</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> in female rats treated with 900 mg/kg/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span></p>
<p>There was no evidence of a mutagenic potential of metformin in the following <span class="Italics">in vitro </span>tests: Ames test (<span class="Italics">S. typhimurium</span>), gene mutation test (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells), or chromosomal aberrations test (human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). Results in the <span class="Italics">in vivo </span>mouse micronucleus test were also negative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span></p>
<p>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First">Canagliflozin</p>
<p>In a juvenile toxicity study in which canagliflozin was dosed directly to young rats from postnatal day (PND) 21 until PND 90 at doses of 4, 20, 65, or 100 mg/kg, increased kidney weights and a dose-related increase in the incidence and severity of renal pelvic and renal tubular dilatation were reported at all dose levels. Exposure at the lowest dose tested was greater than or equal to 0.5 times the maximum clinical dose of 300 mg. The renal pelvic dilatations observed in juvenile animals did not fully reverse within the 1-month recovery period. Similar effects on the developing kidney were not seen when canagliflozin was administered to pregnant rats or rabbits during the period of organogenesis or during a study in which maternal rats were dosed from gestation day (GD) 6 through PND 21 and pups were indirectly exposed <span class="Italics">in utero</span> and throughout lactation.</p>
<p>In embryo-fetal development studies in rats and rabbits, canagliflozin was administered for intervals coinciding with the first trimester period of non-renal organogenesis in humans.</p>
<p>No developmental toxicities were observed at any dose tested other than a slight increase in the number of fetuses with reduced ossification at a dose that was associated with maternal toxicity and that is approximately 19 times the human exposure to canagliflozin at the 300 mg clinical dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First">Canagliflozin and Metformin Combination</p>
<p>Co-administration of canagliflozin and metformin to pregnant rats during the period of organogenesis was neither embryolethal nor teratogenic when tested at doses yielding systemic exposures (AUC) up to 11 and 13 times the maximum recommended human dose (MRHD) (canagliflozin 300 mg and metformin 2000 mg), respectively. Minor skeletal abnormalities (delayed-ossification) in fetuses were observed that were related to the maternal body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreases</span>. Maternal toxicity in rats for canagliflozin when co-administered with metformin was observed at 5.8 and 13 times the human exposure at the MRHD (canagliflozin 300 mg and metformin 2000 mg), respectively.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Canagliflozin has been studied in combination with metformin alone, metformin and sulfonylurea, metformin and a thiazolidinedione (i.e. pioglitazone), and metformin and insulin (with or without other anti-hyperglycemic agents). The efficacy of canagliflozin was compared to a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) and a sulfonylurea (glimepiride).</p>
<p>There have been no clinical efficacy studies conducted with INVOKAMET; however, bioequivalence of INVOKAMET to canagliflozin and metformin co-administered as individual tablets was demonstrated in healthy subjects.</p>
<p>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, treatment with canagliflozin and metformin produced clinically and statistically significant improvements in HbA1C compared to placebo. Reductions in HbA1C were observed across subgroups including age, gender, race, and baseline body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Canagliflozin as Add-on Combination Therapy with Metformin</h2>
<p class="First">A total of 1284 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on metformin monotherapy (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) participated in a 26-week, double-blind, placebo- and active-controlled study to evaluate the efficacy and safety of canagliflozin in combination with metformin. The mean age was 55 years, 47% of patients were men, and the mean baseline eGFR was 89 mL/min/1.73 m<span class="Sup">2</span>. Patients already on the required metformin dose (N=1009) were randomized after completing a 2-week, single-blind, placebo run-in period. Patients taking less than the required metformin dose or patients on metformin in combination with another antihyperglycemic agent (N=275) were switched to metformin monotherapy (at doses described above) for at least 8 weeks before entering the 2-week, single-blind, placebo run-in. After the placebo run-in period, patients were randomized to canagliflozin 100 mg, canagliflozin 300 mg, sitagliptin 100 mg, or placebo, administered once daily as add-on therapy to metformin.</p>
<p>At the end of treatment, canagliflozin 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p&lt;0.001 for both doses) compared to placebo when added to metformin. Canagliflozin 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reduction in fasting plasma glucose (FPG), in improved postprandial glucose (PPG), and in percent body weight reduction compared to placebo when added to metformin (see <a href="#table9">Table 9</a>). Statistically significant (p&lt;0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -5.4 mmHg and -6.6 mmHg with canagliflozin 100 mg and 300 mg, respectively.</p>
<a name="table9"></a><table width="90%">
<caption><span>Table 9: Results from 26-Week  Placebo-Controlled Clinical Study of Canagliflozin in Combination with  Metformin<a name="footnote-reference-30" href="#footnote-30" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Placebo +  Metformin<br>(N=183)</th>
<th class="Rrule" align="center">Canagliflozin  100 mg + Metformin<br>(N=368)</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin<br>(N=367)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-30" href="#footnote-reference-30">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">‡</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">7.96</td>
<td class="Rrule" align="center">7.94</td>
<td class="Rrule" align="center">7.95</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.17</td>
<td class="Rrule" align="center">-0.79</td>
<td class="Rrule" align="center">-0.94</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a name="footnote-reference-31" href="#footnote-31" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.62<a name="footnote-reference-32" href="#footnote-32" class="Sup">‡</a><br>(-0.76, -0.48)</td>
<td class="Rrule" align="center">-0.77<a href="#footnote-32" class="Sup">‡</a><br>(-0.91, -0.64)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">46<a href="#footnote-32" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">58<a href="#footnote-32" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">164</td>
<td class="Rrule" align="center">169</td>
<td class="Rrule" align="center">173</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">-27</td>
<td class="Rrule" align="center">-38</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-31" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-30<a href="#footnote-32" class="Sup">‡</a><br>(-36, -24)</td>
<td class="Rrule" align="center">-40<a href="#footnote-32" class="Sup">‡</a><br>(-46, -34)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">249</td>
<td class="Rrule" align="center">258</td>
<td class="Rrule" align="center">262</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-10</td>
<td class="Rrule" align="center">-48</td>
<td class="Rrule" align="center">-57</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-31" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-38<a href="#footnote-32" class="Sup">‡</a><br>(-49, -27)</td>
<td class="Rrule" align="center">-47<a href="#footnote-32" class="Sup">‡</a><br>(-58, -36)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Body Weight</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">86.7</td>
<td class="Rrule" align="center">88.7</td>
<td class="Rrule" align="center">85.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-1.2</td>
<td class="Rrule" align="center">-3.7</td>
<td class="Rrule" align="center">-4.2</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-31" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-2.5<a href="#footnote-32" class="Sup">‡</a><br>(-3.1, -1.9)</td>
<td class="Rrule" align="center">-2.9<a href="#footnote-32" class="Sup">‡</a><br>(-3.5, -2.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Canagliflozin Compared to Glimepiride, Both as Add-on Combination Therapy with Metformin</h2>
<p class="First">A total of 1450 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on metformin monotherapy (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) participated in a 52-week, double-blind, active-controlled study to evaluate the efficacy and safety of canagliflozin in combination with metformin.</p>
<p>The mean age was 56 years, 52% of patients were men, and the mean baseline eGFR was 90 mL/min/1.73 m<span class="Sup">2</span>. Patients tolerating maximally required metformin dose (N=928) were randomized after completing a 2-week, single-blind, placebo run-in period. Other patients (N=522) were switched to metformin monotherapy (at doses described above) for at least 10 weeks, then completed a 2-week single-blind run-in period. After the 2-week run-in period, patients were randomized to canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride (titration allowed throughout the 52-week study to 6 or 8 mg), administered once daily as add-on therapy to metformin.</p>
<p>As shown in Table 10 and Figure 1, at the end of treatment, canagliflozin 100 mg provided similar reductions in HbA1C from baseline compared to glimepiride when added to metformin therapy. Canagliflozin 300 mg provided a greater reduction from baseline in HbA1C compared to glimepiride, and the relative treatment difference was -0.12% (95% CI: −0.22; −0.02). As shown in Table 10, treatment with canagliflozin 100 mg and 300 mg daily provided greater improvements in percent body weight change, relative to glimepiride.</p>
<a name="table10"></a><table width="90%">
<caption><span>Table 10: Results from 52−Week  Clinical Study Comparing Canagliflozin to Glimepiride in Combination with  Metformin<a name="footnote-reference-33" href="#footnote-33" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Canagliflozin  100 mg + Metformin<br>(N=483)</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin<br>(N=485)</th>
<th class="Rrule" align="center">Glimepiride  (titrated) + Metformin<br>(N=482)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-34" href="#footnote-reference-34">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">‡</a></dt>
<dd>Canagliflozin + metformin is considered non-inferior to glimepiride + metformin because the upper limit of this confidence interval is less than the pre-specified non-inferiority margin of &lt; 0.3%.</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">§</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">7.78</td>
<td class="Rrule" align="center">7.79</td>
<td class="Rrule" align="center">7.83</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.82</td>
<td class="Rrule" align="center">-0.93</td>
<td class="Rrule" align="center">-0.81</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from glimepiride (adjusted mean) (95% CI)<a name="footnote-reference-34" href="#footnote-34" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-0.01<a name="footnote-reference-35" href="#footnote-35" class="Sup">‡</a><br>(-0.11, 0.09)</td>
<td class="Rrule" align="center">-0.12<a href="#footnote-35" class="Sup">‡</a><br>(-0.22, -0.02)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">60</td>
<td class="Rrule" align="center">56</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">165</td>
<td class="Rrule" align="center">164</td>
<td class="Rrule" align="center">166</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-24</td>
<td class="Rrule" align="center">-28</td>
<td class="Rrule" align="center">-18</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from glimepiride (adjusted mean) (95% CI)<a href="#footnote-34" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-6<br>(-10, -2)</td>
<td class="Rrule" align="center">-9<br>(-13, -5)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Body Weight </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">86.8</td>
<td class="Rrule" align="center">86.6</td>
<td class="Rrule" align="center">86.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-4.2</td>
<td class="Rrule" align="center">-4.7</td>
<td class="Rrule" align="center">1.0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Difference from glimepiride (adjusted mean) (95% CI)<a href="#footnote-34" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-5.2<a name="footnote-reference-36" href="#footnote-36" class="Sup">§</a><br>(-5.7, -4.7)</td>
<td class="Rrule" align="center">-5.7<a href="#footnote-36" class="Sup">§</a><br>(-6.2, -5.1)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1:        Mean HbA1C Change at Each Time Point (Completers) and at Week 52 Using Last Observation Carried Forward (mITT Population)</span></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Canagliflozin as Add-on Combination Therapy with Metformin and Sulfonylurea</h2>
<p class="First">A total of 469 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (maximal or near-maximal effective dose) participated in a 26-week, double-blind, placebo-controlled study to evaluate the efficacy and safety of canagliflozin in combination with metformin and sulfonylurea. The mean age was 57 years, 51% of patients were men, and the mean baseline eGFR was 89 mL/min/1.73 m<span class="Sup">2</span>. Patients already on the protocol-specified doses of metformin and sulfonylurea (N=372) entered a 2-week, single-blind, placebo run-in period. Other patients (N=97) were required to be on a stable protocol-specified dose of metformin and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to canagliflozin 100 mg, canagliflozin 300 mg, or placebo administered once daily as add-on to metformin and sulfonylurea.</p>
<p>At the end of treatment, canagliflozin 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p&lt;0.001 for both doses) compared to placebo when added to metformin and sulfonylurea. Canagliflozin 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7.0%, in a significant reduction in fasting plasma glucose (FPG), and in percent body weight reduction compared to placebo when added to metformin and sulfonylurea (see <a href="#table11">Table 11</a>).</p>
<a name="table11"></a><table width="90%">
<caption><span>Table 11: Results from 26−Week Placebo-Controlled  Clinical Study of Canagliflozin in Combination with Metformin and  Sulfonylurea<a name="footnote-reference-37" href="#footnote-37" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Placebo +  Metformin and Sulfonylurea<br>(N=156)</th>
<th class="Rrule" align="center">Canagliflozin  100 mg + Metformin and  Sulfonylurea<br>(N=157)</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin and  Sulfonylurea<br>(N=156)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-37" href="#footnote-reference-37">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">‡</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">8.12</td>
<td class="Rrule" align="center">8.13</td>
<td class="Rrule" align="center">8.13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.13</td>
<td class="Rrule" align="center">-0.85</td>
<td class="Rrule" align="center">-1.06</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a name="footnote-reference-38" href="#footnote-38" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.71<a name="footnote-reference-39" href="#footnote-39" class="Sup">‡</a><br>(-0.90, -0.52)</td>
<td class="Rrule" align="center">-0.92<a href="#footnote-39" class="Sup">‡</a><br>(-1.11, -0.73)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">43<a href="#footnote-39" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">57<a href="#footnote-39" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">170</td>
<td class="Rrule" align="center">173</td>
<td class="Rrule" align="center">168</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">-18</td>
<td class="Rrule" align="center">-31</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-38" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-22<a href="#footnote-39" class="Sup">‡</a><br>(-31, -13)</td>
<td class="Rrule" align="center">-35<a href="#footnote-39" class="Sup">‡</a><br>(-44, -25)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Body Weight</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">90.8</td>
<td class="Rrule" align="center">93.5</td>
<td class="Rrule" align="center">93.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.7</td>
<td class="Rrule" align="center">-2.1</td>
<td class="Rrule" align="center">-2.6</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-38" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-1.4<a href="#footnote-39" class="Sup">‡</a><br>(-2.1, -0.7)</td>
<td class="Rrule" align="center">-2.0<a href="#footnote-39" class="Sup">‡</a><br>(-2.7, -1.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4	Canagliflozin Compared to Sitagliptin, Both as Add-on Combination Therapy with Metformin and Sulfonylurea</h2>
<p class="First">A total of 755 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (near-maximal or maximal effective dose) participated in a 52 week, double-blind, active-controlled study to compare the efficacy and safety of canagliflozin 300 mg versus sitagliptin 100 mg in combination with metformin and sulfonylurea. The mean age was 57 years, 56% of patients were men, and the mean baseline eGFR was 88 mL/min/1.73 m<span class="Sup">2</span>. Patients already on protocol-specified doses of metformin and sulfonylurea (N=716) entered a 2-week single-blind, placebo run-in period. Other patients (N=39) were required to be on a stable protocol-specified dose of metformin and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to canagliflozin 300 mg or sitagliptin 100 mg as add-on to metformin and sulfonylurea.</p>
<p>As shown in Table 12 and Figure 2, at the end of treatment, canagliflozin 300 mg provided greater HbA1C reduction compared to sitagliptin 100 mg when added to metformin and sulfonylurea (p&lt;0.05). Canagliflozin 300 mg resulted in a mean percent change in body weight from baseline of -2.5% compared to +0.3% with sitagliptin 100 mg. A mean change in systolic blood pressure from baseline of -5.06 mmHg was observed with canagliflozin 300 mg compared to +0.85 mmHg with sitagliptin 100 mg.</p>
<a name="table12"></a><table width="75%">
<caption><span>Table 12:        Results from 52−Week  Clinical Study Comparing Canagliflozin to Sitagliptin in Combination with  Metformin and Sulfonylurea<a name="footnote-reference-40" href="#footnote-40" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="50%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin and Sulfonylurea<br>(N=377)</th>
<th class="Rrule" align="center">Sitagliptin  100 mg + Metformin and Sulfonylurea<br>(N=378)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-40" href="#footnote-reference-40">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-41" href="#footnote-reference-41">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-42" href="#footnote-reference-42">‡</a></dt>
<dd>Canagliflozin + metformin+ sulfonylurea is considered non-inferior to sitagliptin + metformin+ sulfonylurea because the upper limit of this confidence interval is less than the pre-specified non-inferiority margin of &lt; 0.3%.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">§</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">8.12</td>
<td class="Rrule" align="center">8.13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-1.03</td>
<td class="Rrule" align="center">-0.66</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from sitagliptin (adjusted mean) (95% CI)<a name="footnote-reference-41" href="#footnote-41" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-0.37<a name="footnote-reference-42" href="#footnote-42" class="Sup">‡</a><br>(-0.50, -0.25)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">35</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">170</td>
<td class="Rrule" align="center">164</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-30</td>
<td class="Rrule" align="center">-6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from sitagliptin (adjusted mean) (95% CI)<a href="#footnote-41" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-24<br>(-30, -18)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Body Weight</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">87.6</td>
<td class="Rrule" align="center">89.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-2.5</td>
<td class="Rrule" align="center">0.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Difference from sitagliptin (adjusted mean) (95% CI)<a href="#footnote-41" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-2.8<a name="footnote-reference-43" href="#footnote-43" class="Sup">§</a><br>(-3.3, -2.2)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 2:        Mean HbA1C Change at Each Time Point (Completers) and at Week 52 Using Last Observation Carried Forward (mITT Population)</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5	Canagliflozin as Add-on Combination Therapy with Metformin and Pioglitazone</h2>
<p class="First">A total of 342 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and pioglitazone (30 or 45 mg/day) participated in a 26-week, double-blind, placebo-controlled study to evaluate the efficacy and safety of canagliflozin in combination with metformin and pioglitazone. The mean age was 57 years, 63% of patients were men, and the mean baseline eGFR was 86 mL/min/1.73 m<span class="Sup">2</span>. Patients already on protocol-specified doses of metformin and pioglitazone (N=163) entered a 2-week, single-blind, placebo run-in period. Other patients (N=181) were required to be on stable protocol-specified doses of metformin and pioglitazone for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to canagliflozin 100 mg, canagliflozin 300 mg, or placebo, administered once daily as add-on to metformin and pioglitazone.</p>
<p>At the of end of treatment, canagliflozin 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p&lt;0.001 for both doses) compared to placebo when added to metformin and pioglitazone. Canagliflozin 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reduction in fasting plasma glucose (FPG), and in percent body weight reduction compared to placebo when added to metformin and pioglitazone (see <a href="#table13">Table 13</a>). Statistically significant (p&lt;0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -4.1 mmHg and -3.5 mmHg with canagliflozin 100 mg and 300 mg, respectively.</p>
<a name="table13"></a><table width="90%">
<caption><span>Table 13:        Results from 26−Week Placebo-Controlled  Clinical Study of Canagliflozin in Combination with Metformin and  Pioglitazone<a name="footnote-reference-44" href="#footnote-44" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Placebo +  Metformin and  Pioglitazone<br>(N=115)</th>
<th class="Rrule" align="center">Canagliflozin  100 mg + Metformin and Pioglitazone<br>(N=113)</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin and Pioglitazone<br>(N=114)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-44" href="#footnote-reference-44">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-45" href="#footnote-reference-45">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-46" href="#footnote-reference-46">‡</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">8.00</td>
<td class="Rrule" align="center">7.99</td>
<td class="Rrule" align="center">7.84</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.26</td>
<td class="Rrule" align="center">-0.89</td>
<td class="Rrule" align="center">-1.03</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a name="footnote-reference-45" href="#footnote-45" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.62<a name="footnote-reference-46" href="#footnote-46" class="Sup">‡</a><br>(-0.81, -0.44)</td>
<td class="Rrule" align="center">-0.76<a href="#footnote-46" class="Sup">‡</a><br>(-0.95, -0.58)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">47<a href="#footnote-46" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">64<a href="#footnote-46" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">164</td>
<td class="Rrule" align="center">169</td>
<td class="Rrule" align="center">164</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">-27</td>
<td class="Rrule" align="center">-33</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-45" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-29<a href="#footnote-46" class="Sup">‡</a><br>(-37, -22)</td>
<td class="Rrule" align="center">-36<a href="#footnote-46" class="Sup">‡</a><br>(-43, -28)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Body Weight</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">94.0</td>
<td class="Rrule" align="center">94.2</td>
<td class="Rrule" align="center">94.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">-0.1</td>
<td class="Rrule" align="center">-2.8</td>
<td class="Rrule" align="center">-3.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a href="#footnote-45" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-2.7<a href="#footnote-46" class="Sup">‡</a><br>(-3.6, -1.8)</td>
<td class="Rrule" align="center">-3.7<a href="#footnote-46" class="Sup">‡</a><br>(-4.6, -2.8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6	Canagliflozin as Add-on Combination Therapy with Insulin (With or Without Other Anti-Hyperglycemic Agents, Including Metformin)</h2>
<p class="First">A total of 1718 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on insulin greater than or equal to 30 units/day or insulin in combination with other antihyperglycemic agents participated in an 18-week, double-blind, placebo-controlled substudy of a cardiovascular study to evaluate the efficacy and safety of canagliflozin in combination with insulin. Of these patients, a subgroup of 432 patients with inadequate glycemic control received canagliflozin or placebo plus metformin and ≥ 30 units/day of insulin over 18 weeks.</p>
<p>In this subgroup, the mean age was 61 years, 67% of patients were men, and the mean baseline eGFR was 81 mL/min/1.73 m<span class="Sup">2</span>. Patients on metformin in combination with basal, bolus, or basal/bolus insulin for at least 10 weeks entered a 2-week, single-blind, placebo run-in period. Approximately 74% of these patients were on a background of metformin and basal/bolus insulin regimen. After the run-in period, patients were randomized to canagliflozin 100 mg, canagliflozin 300 mg, or placebo, administered once daily as add-on to metformin and insulin. The mean daily insulin dose at baseline was 93 units, which was similar across treatment groups.</p>
<p>At the of end of treatment, canagliflozin 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p&lt;0.001 for both doses) compared to placebo when added to metformin and insulin. Canagliflozin 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reductions in fasting plasma glucose (FPG), and in percent body weight reductions compared to placebo (see <a href="#table14">Table 14</a>). Statistically significant (p=0.023 for the 100 mg and p&lt;0.001 for the 300 mg dose) mean change from baseline in systolic blood pressure relative to placebo was –3.5 mmHg and –6 mmHg with canagliflozin 100 mg and 300 mg, respectively. Fewer patients on canagliflozin in combination with metformin and insulin required glycemic rescue therapy: 3.6% of patients receiving canagliflozin 100 mg, 2.7% of patients receiving canagliflozin 300 mg, and 6.2% of patients receiving placebo. An increased incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was observed in this study, which is consistent with the expected increase of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when an agent not associated with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is added to insulin <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>; <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
<a name="table14"></a><table width="90%">
<caption><span>Table 14:        Results from 18−Week Placebo-Controlled  Clinical Study of Canagliflozin in Combination with Metformin and Insulin  ≥ 30 Units/Day<a name="footnote-reference-47" href="#footnote-47" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">Placebo + Metformin  + Insulin<br>(N=145)</th>
<th class="Rrule" align="center">Canagliflozin  100 mg + Metformin + Insulin<br>(N=139)</th>
<th class="Rrule" align="center">Canagliflozin  300 mg + Metformin + Insulin<br>(N=148)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-47" href="#footnote-reference-47">*</a></dt>
<dd>Intent-to-treat population using last observation in study prior to glycemic rescue therapy</dd>
<dt><a name="footnote-48" href="#footnote-reference-48">†</a></dt>
<dd>Least squares mean adjusted for baseline value and stratification factors</dd>
<dt><a name="footnote-49" href="#footnote-reference-49">‡</a></dt>
<dd>p≤0.001</dd>
<dt><a name="footnote-50" href="#footnote-reference-50">§</a></dt>
<dd>p≤0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">HbA1C (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean)</td>
<td class="Rrule" align="center">8.15</td>
<td class="Rrule" align="center">8.20</td>
<td class="Rrule" align="center">8.22</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">0.03</td>
<td class="Rrule" align="center">-0.64</td>
<td class="Rrule" align="center">-0.79</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (95% CI)<a name="footnote-reference-48" href="#footnote-48" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-0.66<a name="footnote-reference-49" href="#footnote-49" class="Sup">‡</a><br>(-0.81, -0.51)</td>
<td class="Rrule" align="center">-0.82<a href="#footnote-49" class="Sup">‡</a><br>(-0.96, -0.67)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Percent of patients achieving HbA1C &lt; 7%</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">19<a name="footnote-reference-50" href="#footnote-50" class="Sup">§</a>
</td>
<td class="Rrule" align="center">29<a href="#footnote-49" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline</td>
<td class="Rrule" align="center">163</td>
<td class="Rrule" align="center">168</td>
<td class="Rrule" align="center">167</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">-16</td>
<td class="Rrule" align="center">-24</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (97.5% CI)<a href="#footnote-48" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-16<a href="#footnote-49" class="Sup">‡</a><br>(-28, -5)</td>
<td class="Rrule" align="center">-25<a href="#footnote-49" class="Sup">‡</a><br>(-36, -14)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Body Weight</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (mean) in kg</td>
<td class="Rrule" align="center">102.3</td>
<td class="Rrule" align="center">99.7</td>
<td class="Rrule" align="center">101.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  % change from baseline (adjusted mean)</td>
<td class="Rrule" align="center">0.0</td>
<td class="Rrule" align="center">-1.7</td>
<td class="Rrule" align="center">-2.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean) (97.5% CI)<a href="#footnote-48" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">-1.7<a href="#footnote-49" class="Sup">‡</a><br>(-2.4, -1.0)</td>
<td class="Rrule" align="center">-2.7<a href="#footnote-49" class="Sup">‡</a><br>(-3.4, -2.0)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">INVOKAMET (canagliflozin and metformin hydrochloride) tablets are available in the strengths and packages listed below:</p>
<p>Canagliflozin 50 mg and metformin hydrochloride 500 mg tablets are immediate-release, capsule-shaped, white film-coated tablets with "CM" on one side and "155" on the other side.</p>
<ul class="Disc"><li>NDC 50458-540-60    Bottle of 60</li></ul>
<p>Canagliflozin 50 mg and metformin hydrochloride 1,000 mg tablets are immediate-release, capsule-shaped, beige film-coated tablets with "CM" on one side and "551" on the other side.</p>
<ul class="Disc"><li>NDC 50458-541-60    Bottle of 60</li></ul>
<p>Canagliflozin 150 mg and metformin hydrochloride 500 mg tablets are immediate-release, capsule-shaped, yellow film-coated tablets with "CM" on one side and "215" on the other side.</p>
<ul class="Disc"><li>NDC 50458-542-60    Bottle of 60</li></ul>
<p>Canagliflozin 150 mg and metformin hydrochloride 1,000 mg tablets are immediate-release, capsule-shaped, purple film-coated tablets with "CM" on one side and "611" on the other side.</p>
<ul class="Disc"><li>NDC 50458-543-60    Bottle of 60</li></ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Storage and Handling</p>
<p>Keep out of reach of children.</p>
<p>Store at 68–77°F (20–25°C); excursions permitted between 59°F and 86°F (15°C and 30°C) [see USP Controlled Room Temperature]. Store in the original container.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-Approved Patient Labeling (Medication Guide)<span class="Italics">.</span></p>
<ul class="Disc">
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></span>: Explain the risks of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, its symptoms, and conditions that predispose to its development, as noted in <span class="Italics">Warnings and Precautions (5.1)</span>. Advise patients to discontinue INVOKAMET immediately and to promptly notify their healthcare provider if unexplained <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or other nonspecific symptoms occur. Once a patient is stabilized on INVOKAMET, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, which are common during initiation of metformin, are unlikely to recur. Later occurrence of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</li>
<li>Instruct patients to keep INVOKAMET in the original bottle to protect from moisture. Do not put INVOKAMET in pill boxes or pill organizers.</li>
<li>Counsel patients against excessive alcohol intake while receiving INVOKAMET.</li>
<li>Inform patients about importance of regular testing of renal function and hematological parameters while receiving INVOKAMET.</li>
<li>Advise patients to seek medical advice promptly during periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, as medication requirements may change.</li>
<li>Instruct patients to take INVOKAMET only as prescribed twice daily with food. If a dose is missed, advise patients not to take two doses of INVOKAMET at the same time.</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>: Inform patients that symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur with INVOKAMET and advise them to contact their doctor if they experience such symptoms <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>. Inform patients that <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may increase the risk for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and to have adequate fluid intake.</li>
<li>
<span class="Underline">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Females</span>: Inform female patients that vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>) may occur and provide them with information on the signs and symptoms of a vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>. Advise them of treatment options and when to seek medical advice <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
<li>
<span class="Underline">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Males</span>: Inform male patients that <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of penis (e.g., <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>) may occur, especially in uncircumcised males and patients with prior history. Provide them with information on the signs and symptoms of <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> and <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span> (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: Inform patients that serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, have been reported with canagliflozin. Advise patients to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and to take no more drug until they have consulted prescribing physicians <span class="Italics">[see <a href="#s5.8">Warnings and Precautions (5.8)</a>]</span>.</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span>: Inform patients of the potential for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Provide them with information on the symptoms of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Advise them to seek medical advice if such symptoms occur.</li>
<li>
<span class="Underline">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></span>: Inform patients that bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been reported in patients taking canagliflozin. Provide them with information on factors that may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk.</li>
<li>
<span class="Underline">Laboratory Tests</span>: Inform patients that they will test positive for glucose in their urine while on INVOKAMET <span class="Italics">[see <a href="#s7.2">Drug Interactions (7.2)</a>]</span>.</li>
<li>
<span class="Underline">Pregnancy</span>: Inform female patients of child bearing age that the use of INVOKAMET during pregnancy has not been studied in humans, and to use INVOKAMET during pregnancy only if the potential benefit justifies the potential risk to the fetus. Instruct patients to report pregnancies to their physicians as soon as possible <span class="Italics">[see <a href="#s8.1">Use in Specific Populations (8.1)</a>]</span>.</li>
<li>
<span class="Underline">Nursing Mothers</span>: Inform nursing mothers to discontinue INVOKAMET or nursing, taking into account the importance of drug to the mother <span class="Italics">[see <a href="#s8.3">Use in Specific Populations (8.3)</a>]</span>.</li>
<li>Inform patients that the most common adverse reactions associated with canagliflozin are genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and increased urination. Most common adverse reactions associated with metformin are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560</p>
<p>Finished product manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, PR 00778</p>
<p>Licensed from Mitsubishi Tanabe Pharma Corporation</p>
<p>© 2014 Janssen Pharmaceuticals, Inc.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="mg"></a><a name="section-17"></a><p></p>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top">This Medication Guide has been approved by the U.S. Food and Drug Administration.                                                                           Revised SEP/2015</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">Medication Guide<br>INVOKAMET<span class="Sup">®</span> (in vok' a met)<br>(canagliflozin and metformin hydrochloride)<br>Tablets</span></td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<p class="First"><a name="important"></a><span class="Bold">What is the most important information I should know about INVOKAMET?<br>INVOKAMET can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>.</span> Metformin, 1 of the medicines in INVOKAMET, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> (a build-up of lactic acid in the blood) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency and must be treated in the hospital.<br><span class="Bold">Stop taking INVOKAMET and call your doctor right away if you have any of the following symptoms which could be signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span><table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li>you feel very weak or tired</li>
<li>you have trouble breathing</li>
<li>you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pains</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>you have a slow or irregular heartbeat</li>
</ul></td>
<td align="left"><ul class="Circle">
<li>you have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>you have unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or sleep longer than usual</li>
<li>you feel dizzy or lightheaded</li>
</ul></td>
</tr></tbody>
</table>
</li></ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">You have a higher chance of getting <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with INVOKAMET if you:<ul class="Circle">
<li>have kidney problems or your kidneys are affected by certain x-ray tests that use injectable dye. People whose kidneys are not working properly should not take INVOKAMET.</li>
<li>have liver problems.</li>
<li>have <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> that requires treatment with medicines.</li>
<li>drink alcohol very often, or drink a lot of alcohol in short-term "binge" drinking.</li>
<li>get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> can also happen when you sweat a lot with activity or exercise and do not drink enough fluids.</li>
<li>have surgery.</li>
<li>have a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</li>
<li>are 80 years of age or older and have not had your kidneys tested.</li>
</ul>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">The best way to keep from having a problem with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor will decide to stop your INVOKAMET for a while if you have any of these things.<br><span class="Bold">INVOKAMET can have other serious side effects. See "<a href="#sideeffects">What are the possible side effects of INVOKAMET?</a>"</span>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">What is INVOKAMET?</span><ul class="Disc">
<li>INVOKAMET contains 2 prescription medicines called canagliflozin (INVOKANA) and metformin hydrochloride (GLUCOPHAGE). INVOKAMET can be used along with diet and exercise to improve blood sugar (glucose) control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> when treatment with either canagliflozin or metformin has not controlled your blood sugar.</li>
<li>INVOKAMET is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>INVOKAMET is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in blood or urine).</li>
<li>It is not known if INVOKAMET is safe and effective in children under 18 years of age.</li>
</ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<p class="First"><a name="nottake"></a><span class="Bold">Who should not take INVOKAMET?<br>Do not take INVOKAMET if you:</span></p>
<ul class="Disc">
<li>have severe kidney problems or are on dialysis.</li>
<li>have a condition called <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in the blood or urine)</li>
<li>are allergic to canagliflozin, metformin, or any of the ingredients in INVOKAMET. See the end of this Medication Guide for a list of ingredients in INVOKAMET. Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to INVOKAMET may include:<table class="Noautorules" width="100%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="45%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle"><li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li></ul></td>
<td align="left"><ul class="Circle"><li>raised red patches on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</li></ul></td>
<td align="left"><ul class="Circle"><li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing</li></ul></td>
</tr></tbody>
</table>
</li>
</ul>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"> </td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">What should I tell my doctor before taking INVOKAMET?</span><br>Before you take INVOKAMET, tell your doctor if you:<ul class="Disc">
<li>have kidney problems.</li>
<li>have liver problems.</li>
<li>are on a low sodium (salt) diet. Your doctor may change your diet or your dose of INVOKAMET.</li>
<li>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to INVOKAMET.</li>
<li>are going to get an injection of dye or contrast agents for an x-ray procedure. INVOKAMET will need to be stopped for a short time. Talk to your doctor about when you should stop INVOKAMET and when you should start INVOKAMET again. See "<span class="Bold"><a href="#important">What is the most important information I should know about INVOKAMET?</a></span>"</li>
<li>have heart problems, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</li>
<li>drink alcohol very often, or drink a lot of alcohol in short-term "binge" drinking.</li>
<li>have other medical conditions.</li>
<li>are pregnant or plan to become pregnant. It is not known if INVOKAMET will harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if INVOKAMET passes into your breast milk. Talk with your doctor about the best way to feed your baby if you are taking INVOKAMET.</li>
</ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</span><br>INVOKAMET may affect the way other medicines work and other medicines may affect how INVOKAMET works. Especially tell your doctor if you take:</td></tr>
<tr>
<td class="Lrule" align="left"><ul class="Disc">
<li>diuretics (water pills)</li>
<li>phenytoin or phenobarbital (used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>)</li>
<li>digoxin (Lanoxin<span class="Sup">®</span>)* (used to treat heart problems)</li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li>rifampin (used to treat or prevent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>)</li>
<li>ritonavir (Norvir<span class="Sup">®</span>, Kaletra<span class="Sup">®</span>)* (used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
</ul></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Ask your doctor or pharmacist for a list of these medicines if you are not sure if your medicine is listed above.<br>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">How should I take INVOKAMET?</span><ul class="Disc">
<li>Take INVOKAMET by mouth 2 times each day with meals exactly as your doctor tells you to take it. Taking INVOKAMET with meals may lower your chance of having an <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>.</li>
<li>Your doctor will tell you how much INVOKAMET to take and when to take it. Your doctor may change your dose if needed.</li>
<li>Your doctor may tell you to take INVOKAMET along with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. Low blood sugar can happen more often when INVOKAMET is taken with certain other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. See "<span class="Bold"><a href="#sideeffects">What are the possible side effects of INVOKAMET?</a></span>"</li>
<li>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take 2 doses of INVOKAMET at the same time. Talk to your doctor if you have questions about a missed dose.</li>
<li>If you take too much INVOKAMET, call your doctor or go to the nearest hospital emergency room right away.</li>
<li>When your body is under some types of stress, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (such as a car <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, the amount of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine you need may change. Tell your doctor right away if you have any of these conditions and follow your doctor's instructions.</li>
<li>Stay on your prescribed diet and exercise program while taking INVOKAMET.</li>
<li>Check your blood sugar as your doctor tells you to.</li>
<li>INVOKAMET will cause your urine to test positive for glucose.</li>
<li>Your doctor may do certain blood tests before you start INVOKAMET and during treatment as needed. Your doctor may change your dose of INVOKAMET based on the results of your blood tests.</li>
<li>Your doctor will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood tests, including your blood sugar levels and your hemoglobin A1C.</li>
</ul>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">What should I avoid while taking INVOKAMET?</span><ul class="Disc"><li>Avoid drinking alcohol very often, or drinking a lot of alcohol in a short period of time ("binge" drinking). It can increase your chances of getting serious side effects.</li></ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<p class="First"><a name="sideeffects"></a><span class="Bold">What are the possible side effects of INVOKAMET?<br>INVOKAMET may cause serious side effects including:</span></p>
<ul class="Disc">
<li>See "<span class="Bold"><a href="#important">What is the most important information I should know about INVOKAMET?</a></span>"</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</span> INVOKAMET can cause some people to have <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (the loss of body water and salt). <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> may cause you to feel dizzy, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lightheaded, or weak, especially when you stand up (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>).<br>You may be at higher risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> if you:<ul class="Circle">
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>take medicines to lower your blood pressure, including diuretics (water pill)</li>
<li>are on a low sodium (salt) diet</li>
<li>have kidney problems</li>
<li>are 65 years of age or older</li>
</ul>
</li>
<li><span class="Bold">kidney problems</span></li>
<li><span class="Bold">a high amount of potassium in your blood</span></li>
<li>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> If you take INVOKAMET with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKAMET. Signs and symptoms of low blood sugar may include:<table class="Noautorules" width="100%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>fast heartbeat</li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold">vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</span> Women who take INVOKAMET may get vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>. Symptoms of a vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4162573" conceptname="Vaginal odor">vaginal odor</span></li>
<li>white or yellowish <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> (discharge may be lumpy or look like cottage cheese)</li>
<li><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">vaginal itching</span></li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the penis (<span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>).</span> Men who take INVOKAMET may get a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the skin around the penis. Certain men who are not circumcised may have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the penis include:<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the penis</li>
<li>foul smelling discharge from the penis</li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the penis</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the skin around the penis</li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">Talk to your doctor about what to do if you get symptoms of a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the vagina or penis. Your doctor may suggest you use an over-the-counter antifungal medicine. Talk to your doctor right away if you use an over-the-counter antifungal medication and your symptoms do not go away.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2"><ul class="Disc">
<li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</span> If you have any symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, stop taking INVOKAMET and call your doctor right away or go to the nearest hospital emergency room. See <span class="Bold">"<a href="#nottake">Who should not take INVOKAMET?</a>".</span> Your doctor may give you a medicine for your <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> and prescribe a different medicine for your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>
<span class="Bold">broken bones (<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>).</span> Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been seen in patients taking canagliflozin. Talk to your doctor about factors that may increase your risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</li>
<li>
<span class="Bold">low vitamin B<span class="Sub">12</span> (vitamin B<span class="Sub">12</span> deficiency).</span> Using metformin for long periods of time may cause a decrease in the amount of vitamin B<span class="Sub">12</span> in your blood, especially if you have had low vitamin B<span class="Sub">12</span> blood levels before. Your doctor may do blood tests to check your vitamin B<span class="Sub">12</span> levels.</li>
</ul></td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">Other common side effects of INVOKAMET include:</td></tr>
<tr>
<td class="Lrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span></li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="2"><ul class="Disc"><li>changes in urination, including urgent need to urinate more often, in larger amounts, or at night</li></ul></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of INVOKAMET. For more information, ask your doctor or pharmacist.<br><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span><br>You may also report side effects to Janssen Pharmaceuticals, Inc. at 1-800-526-7736.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">How should I store INVOKAMET?</span><ul class="Disc">
<li>Store INVOKAMET at room temperature between 68°F to 77°F (20°C to 25°C).</li>
<li>Store in the original container to protect from moisture. <span class="Bold">Do not</span> put INVOKAMET in pill boxes or pill organizers.</li>
</ul>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Keep INVOKAMET and all medicines out of the reach of children.</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">General information about the safe and effective use of INVOKAMET.</span><br>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use INVOKAMET for a condition for which it was not prescribed. Do not give INVOKAMET to other people, even if they have the same symptoms you have. It may harm them.<br>This Medication Guide summarizes the most important information about INVOKAMET. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about INVOKAMET that is written for healthcare professionals.<br><span class="Bold">For more information about INVOKAMET, call 1-800-526-7736 or visit our website at www.invokamet.com.</span>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">What are the ingredients of INVOKAMET?</span><br>Active ingredients: canagliflozin and metformin hydrochloride<br>Inactive ingredients: The tablet core contains croscarmellose sodium, hypromellose, magnesium stearate, and microcrystalline cellulose. The magnesium stearate is vegetable-sourced. In addition, the tablet coating contains Macrogol/PEG, polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, iron oxide yellow (50 mg/1,000 mg and 150 mg/500 mg tablets only), iron oxide red (50 mg/1,000 mg, 150 mg/500 mg and 150 mg/1,000 mg tablets only), and iron oxide black (150 mg/1,000 mg tablets only).</td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="2">* The brands listed are trademarks of their respective owners and are not trademarks of Janssen Pharmaceuticals, Inc.<br>Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560. Manufactured by: Janssen Ortho, LLC, Gurabo, PR 00778. Licensed from Mitsubishi Tanabe Pharma Corporation. © 2014 Janssen Pharmaceuticals, Inc.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg/500 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458<span class="Bold">-540-</span>60<br>60 tablets</p>
<p><span class="Bold">Invokamet</span><span class="Sup">®</span><br><span class="Bold">(canagliflozin and<br>metformin HCl)<br>Tablets 50 mg/500 mg</span></p>
<p><span class="Bold">Dispense with Medication Guide</span></p>
<p><span class="Bold">Store in the original container.</span></p>
<p><span class="Bold">Rx only</span><br>Janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg/500 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg/1000 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458<span class="Bold">-541-</span>60<br>60 tablets</p>
<p><span class="Bold">Invokamet</span><span class="Sup">®</span><br><span class="Bold">(canagliflozin and<br>metformin HCl)<br>Tablets 50 mg/1,000 mg</span></p>
<p><span class="Bold">Dispense with Medication Guide</span></p>
<p><span class="Bold">Store in the original container.</span></p>
<p><span class="Bold">Rx only</span><br>Janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg/1000 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg/500 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458<span class="Bold">-542-</span>60<br>60 tablets</p>
<p><span class="Bold">Invokamet</span><span class="Sup">®</span><br><span class="Bold">(canagliflozin and<br>metformin HCl)<br>Tablets 150 mg/500 mg</span></p>
<p><span class="Bold">Dispense with Medication Guide</span></p>
<p><span class="Bold">Store in the original container.</span></p>
<p><span class="Bold">Rx only</span><br>Janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg/500 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg/1000 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 50458<span class="Bold">-543-</span>60<br>60 tablets</p>
<p><span class="Bold">Invokamet</span><span class="Sup">®</span><br><span class="Bold">(canagliflozin and<br>metformin HCl)<br>Tablets 150 mg/1,000 mg</span></p>
<p><span class="Bold">Dispense with Medication Guide</span></p>
<p><span class="Bold">Store in the original container.</span></p>
<p><span class="Bold">Rx only</span><br>Janssen</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg/1000 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1&amp;name=invokamet-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INVOKAMET 		
					</strong><br><span class="contentTableReg">canagliflozin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-540</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>canagliflozin</strong> (canagliflozin anhydrous) </td>
<td class="formItem">canagliflozin anhydrous</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>metformin hydrochloride</strong> (metformin) </td>
<td class="formItem">metformin hydrochloride</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CM;155</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-540-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-540-91</td>
<td class="formItem">10  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204353</td>
<td class="formItem">08/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INVOKAMET 		
					</strong><br><span class="contentTableReg">canagliflozin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-541</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>canagliflozin</strong> (canagliflozin anhydrous) </td>
<td class="formItem">canagliflozin anhydrous</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>metformin hydrochloride</strong> (metformin) </td>
<td class="formItem">metformin hydrochloride</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CM;551</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-541-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-541-91</td>
<td class="formItem">10  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204353</td>
<td class="formItem">08/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INVOKAMET 		
					</strong><br><span class="contentTableReg">canagliflozin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-542</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>canagliflozin</strong> (canagliflozin anhydrous) </td>
<td class="formItem">canagliflozin anhydrous</td>
<td class="formItem">150 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>metformin hydrochloride</strong> (metformin) </td>
<td class="formItem">metformin hydrochloride</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CM;215</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-542-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-542-91</td>
<td class="formItem">10  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204353</td>
<td class="formItem">08/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INVOKAMET 		
					</strong><br><span class="contentTableReg">canagliflozin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-543</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>canagliflozin</strong> (canagliflozin anhydrous) </td>
<td class="formItem">canagliflozin anhydrous</td>
<td class="formItem">150 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>metformin hydrochloride</strong> (metformin) </td>
<td class="formItem">metformin hydrochloride</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CM;611</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-543-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-543-91</td>
<td class="formItem">10  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204353</td>
<td class="formItem">08/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Pharmaceuticals, Inc.
							(063137772)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho LLC (Gurabo)</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">MANUFACTURE(50458-540, 50458-541, 50458-542, 50458-543), ANALYSIS(50458-540), PACK(50458-540, 50458-541, 50458-542, 50458-543), LABEL(50458-540, 50458-541, 50458-542, 50458-543)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica NV (Geel)</td>
<td class="formItem"></td>
<td class="formItem">374747970</td>
<td class="formItem">API MANUFACTURE(50458-540, 50458-541, 50458-542, 50458-543), ANALYSIS(50458-540, 50458-541, 50458-542, 50458-543)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Granules India Limited</td>
<td class="formItem"></td>
<td class="formItem">918457644</td>
<td class="formItem">API MANUFACTURE(50458-540, 50458-541, 50458-542, 50458-543), ANALYSIS(50458-540, 50458-541, 50458-542, 50458-543)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Research &amp; Development (Beerse)</td>
<td class="formItem"></td>
<td class="formItem">370005019</td>
<td class="formItem">ANALYSIS(50458-540, 50458-541, 50458-542, 50458-543)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">063137772</td>
<td class="formItem">ANALYSIS(50458-540, 50458-541, 50458-542, 50458-543)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>caf0d926-f112-4cbe-8a88-882258d0c11e</div>
<div>Set id: 6868666b-c25e-40d1-9d1f-306bbe9390c1</div>
<div>Version: 4</div>
<div>Effective Time: 20150916</div>
</div>
</div> <div class="DistributorName">Janssen Pharmaceuticals, Inc.</div></p>
</body></html>
